

# Exhibit 1

Case Nos.

3:16-cv-02056-MPS

3:19-cv-00710-MPS

3:20-cv-00802-MPS

**IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF  
CONNECTICUT**

**The State of Connecticut, *et al.***

**Plaintiffs,**

**v.**

**3:16-cv-02056-MPS**

**Aurobindo Pharma USA, Inc., *et al.***

**Defendants.**

**SETTLEMENT AGREEMENT**

This Settlement Agreement is made and entered into this May 8, 2026 by and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General (as defined below) (collectively, the “Parties”).

WHEREAS, the States are prosecuting claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.) (collectively, the “Actions” or “State Actions”);

WHEREAS, the States allege in the Actions that Glenmark violated various antitrust and consumer protection laws by price-fixing and allocating markets for specified drugs;

WHEREAS, Glenmark has not conceded or admitted any liability in the Actions, and have asserted a number of defenses to the claims of the States;

WHEREAS, arm’s-length settlement negotiations have taken place between the States and Glenmark, and the result is this Settlement Agreement, which embodies all the terms and conditions of the settlement between the States and Glenmark (the “Settlement Agreement”);

WHEREAS, the States have concluded that it is in the best interests of the States to enter into this Settlement Agreement; and WHEREAS, Glenmark has concluded that it is in the best interests of Glenmark to enter into this Settlement Agreement;

NOW, THEREFORE, in exchange for the mutual obligations described below, the States and Glenmark hereby enter into this Settlement Agreement on the following terms and conditions:

## **I. DEFINITIONS**

A. “Attorneys General” are defined as the Attorneys General of each state, commonwealth, district, and territory that asserts claims in the State Actions upon remand from the MDL, as well as those that are otherwise signatories to this Agreement.

B. “Code” is defined as the Internal Revenue Code of 1986, as amended.

C. “Conduct” means any act or omission of the Glenmark Releasees, as defined in Paragraph L. of this Section, or of persons or entities alleged to be co-conspirators of the Glenmark Releasees concerning price fixing, market allocation, bid-rigging, and/or any other anticompetitive and/or unfair conduct based in whole or in part on the allegations in the Actions, in connection with the manufacture, sale, and/or distribution of Drugs at Issue or any other generic drug for which claims could have been asserted based on any facts alleged in any of the complaints filed or otherwise pending at any time in the Actions, including all formulations and

strengths of those drugs, and/or any overarching conspiracy claims involving any of the Drugs at Issue or based in whole or in part on facts alleged in the Actions.

D. “Eligible Consumers” are defined as natural persons for whom an Attorney General can seek in this Action, restitution, or disgorgement in a sovereign, quasi-sovereign, law enforcement equitable capacity, whether pursuant to the Attorney General’s *parens patriae* authority or otherwise. For purposes of clarity, the term “Eligible Consumers” does not include any State Entity, any county, city, town, or other local entity, or any Corporate Entity. Nothing in this agreement shall require a natural person to release their claims, nor should this agreement be read to release the claims of a natural person, as a condition to be an Eligible Consumer.

E. “Corporate Entities” are defined as corporate (and other business) entities for whom the Attorneys General of Idaho and Washington have asserted an exclusive claim in the Actions, whether pursuant to the Attorneys General’s *parens patriae* authority or otherwise.<sup>1</sup>

F. “Defendant” means any party named as a defendant in any of the Actions at any time up to and including the date of the court’s Final Approval Order, as defined in Paragraph J of this Section.

G. “Drugs at Issue” means the drugs listed in Appendix A.

H. “Effective Date” shall be the later of the date on which the final signatory of this Agreement executes this Agreement or Glenmark elects to proceed with the Agreement pursuant to Section II.A.

I. “Enforcement Period” means a 7-year period from the execution of this Settlement Agreement, with an option for the States of an additional 3 years.

J. “Final Approval Order” means the order to be entered by the District Court in the Actions which gives final approval of this Settlement Agreement and releases all Released and Resolved Claims, as defined in Paragraph I.R of this Section. The Parties intend for the Final Approval Order to include provisions: (1) finding this Settlement Agreement (i) as having been entered into in good faith and (ii) as being fair, reasonable, and adequate, and directing its consummation pursuant to its terms, as to the State Releasors, as defined in Paragraph I.V of this Section; (2) finding that the notice given constitutes due, adequate, and sufficient notice and meets the requirements of due process and the Federal Rules of Civil Procedure; (3) incorporating the releases and resolutions set forth in Section IV, and forever barring the State Releasors from asserting any Released and Resolved Claims (as defined in Section IV); (4) retaining exclusive jurisdiction over the Settlement and this Agreement, including the administration and consummation of this Settlement; (5) directing that all claims by and on behalf of the State Releasors be dismissed with prejudice as to Glenmark Releasees only, except,

---

<sup>1</sup> States that have non-exclusive authority to assert claims for corporate or other business entities covenant not to pursue those claims, but do not release those claims. For the avoidance of doubt, Illinois covenants not to pursue claims it brought or could have brought on behalf of corporate (and other business) entities residing in Illinois.



to the extent such claims are on behalf of Eligible Consumers, such claims are dismissed without prejudice to Eligible Consumer's ability to pursue or litigate those claims whether individually or as a class, and, except as provided for herein, with prejudice and without costs or attorney's fees recoverable under 15 U.S.C. § 15(a); and (6) determining pursuant to Fed. R. Civ. P. 54(b) that there is no just reason for delay and directing that the Final Approval Order in the Actions as to the Glenmark Releasees shall be final and immediately appealable.

K. "Generic Pharmaceutical Products" shall mean the generic version of any brand name drug, including all dosages, forms, and strengths of such drug, regardless of whether they are included in any of the complaints filed in the Actions or in the MDL.

L. "Glenmark Releasees" are defined as Glenmark and its parents, subsidiaries, and affiliates, and their respective predecessors, successors, heirs, executors, administrators, and assigns, as well as any current and former officers, directors, employees, attorneys, stockholders, principals, managers, partners, members, agents, representatives, trustees, insurers, and owners thereof. For the avoidance of doubt, Glenmark Releasees include the following individual defendants named in the Actions: Mitchell Blashinsky, James Brown, and James Grauso.<sup>2</sup>

M. "Local Entity(ies)" means any county, city, town, or other local governmental entity.

N. "Notice Period" means the time period allotted for those Eligible Consumers and Corporate Entities on whose behalf the Attorneys General have asserted claims, and anyone else for whom notice is required to (i) object to this Settlement or (ii) file a timely and valid request for exclusion.

O. "Notice Plan" means the plan specifying the manner and content of notifying Eligible Consumers and eligible Corporate Entities of this Settlement Agreement.. The Parties contemplate that the Notice Plan will take ninety (90) days or such other time period set by the District Court. The Notice Plan will specify the way in which Eligible Consumers and eligible Corporate Entities are to be notified of the States' Actions and this Settlement Agreement. The Notice Plan will recognize a second notification to Eligible Consumers and/or eligible Corporate Entities, potentially following a later settlement, may be necessary prior to distribution of funds.

P. "Preliminary Approval Order" means an order to be entered by the District Court that preliminarily approves this Settlement Agreement. The Parties intend that the Preliminary Approval Order will include the following provisions: (1) preliminary approval of this Settlement Agreement as having been entered into in good faith and as fair, reasonable, and adequate to the extent federal court approval is required; ; and (2) approval of the Notice Plan.

Q. "Released and Resolved Claims" shall be defined as those claims released and

---

<sup>2</sup> The scope of this release does not include any current or former Glenmark employee named as an individual defendant prior to the Effective Date with respect to that individual's conduct while employed at any company other than Glenmark.

resolved as to the Glenmark Releasees as further below in Section IV. For the avoidance of doubt and as detailed in this agreement, Released and Resolved Claims does not include any claim held by an Eligible Consumer, either brought or not brought, by the Eligible Consumer in their individual capacity, or by a representative putative or certified class on behalf of Eligible Consumers under any state's law.

R. "States" means all states, commonwealths, districts, and territories that assert claims in the State Actions, including Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, Virgin Islands, Washington, West Virginia, Wisconsin, and Wyoming in their sovereign, proprietary, or any other capacities.<sup>3</sup>

S. "State Actions" or "Actions" means the following cases: *State of Connecticut et al. v. Aurobindo Pharma USA, Inc. et al.*, No. 2:17-cv-3768 (E.D. Pa.); *State of Connecticut v. Aurobindo Pharma USA, Inc.*, No. 3:16-cv-2056 (D. Conn.); *State of Connecticut v. Teva Pharmaceuticals USA, Inc.*, No. 2:19-cv-02407 (E.D. Pa.); *State of Connecticut v. Teva Pharmaceuticals USA, Inc.*, No. 3:19-cv-710 (D. Conn.); *State of Connecticut, et al. v. Sandoz Inc. et al.*, No. 2:20-cv-03539 (E.D. Pa.); *State of Connecticut v. Sandoz, Inc.*, No. 3:20-cv-00802 (D. Conn) and any other action or proceeding asserting claims based on the Conduct, filed or otherwise pursued by or on behalf of any of the Attorneys General or any of the State Entities listed on Appendix B.

T. "State Entity" means any agency, bureau, board, commission, committee, department, division, or other organizational unit of any state government, except for those of any county, city, town, or other local entity or political subdivision, including but not limited to those identified in Appendix B.

U. "State Releasers" means the (a) Attorneys General and State Entities listed on Appendix B (which include, among other State Entities, each State's Medicaid agency); (b) State Entities that accept a distribution of settlement proceeds from the Attorneys General's settlements of the State Actions, (c) the Corporate Entities on whose behalf the Attorneys General assert claims, to the extent those Corporate Entities do not submit a timely and valid

---

<sup>3</sup> This includes claims assigned to the State of Florida, *see, e.g., State of Connecticut, et al. v. Sandoz Inc. et al.*, Amended Complaint, No. 2:20-cv-03539, ECF No. 62, ¶ 1860 (noting that certain claims of Minnesota Multistate Contracting Alliance for Pharmacy ("MMCAP") and/or Cardinal Health, Inc. have been assigned to the state of Florida), claims assigned to the State of California, *see id.* ¶ 2117 (noting that certain "vendors and intermediaries" assigned claims to the state of California), and claims assigned to the State of New York, *see, e.g., State of Connecticut, et al. v. Teva Pharmaceuticals USA, Inc.*, Amended Complaint, No. 2:19-cv-02407, ECF No. 106, ¶ 1586 (noting that certain claims of MMCAP and/or Cardinal Health, Inc. have been assigned to the state of New York).

request for exclusion from the settlement under this Agreement and the Actions.

## II. CONDITION TO EFFECTIVENESS OF AGREEMENT

A. The Attorneys General will have 60 calendar days from the date of Glenmark's signature to execute this Agreement, or at least until July 7, 2026. If all Attorneys General have not executed this Agreement within 60 calendar days, Glenmark shall have 30 calendar days to determine, in its sole discretion, whether to extend the Attorneys General's time to execute this agreement for an additional time period, whether sufficient Attorneys General have executed this agreement to proceed with this Agreement, or whether it does not wish to proceed. Glenmark shall provide its determination in writing to the Attorneys General. If Glenmark determines to proceed, the Attorneys General will promptly move for preliminary approval as set forth in Paragraph V.A., and the first payment detailed in Section III will be owed to the Attorneys General within 30 days of preliminary approval by the Court. Should all Attorneys General execute this agreement prior to July 7, 2026, then the Glenmark notice provisions of this Paragraph shall not apply, the Attorneys General will move for preliminary approval no earlier than July 7, 2026 and the first payment detailed in Section III will be owed to the Attorneys General within 30 days of preliminary approval.

B. If Glenmark determines to proceed with this agreement despite the fact that certain Attorneys General have declined to proceed with the Agreement, Glenmark shall be entitled to a reduction in the Settlement Payment by an amount listed for each of non-settling States listed in Appendix D. If Glenmark determines not to proceed, this Agreement will have no further effect.

## III. SETTLEMENT PAYMENT AND USE OF THAT PAYMENT

A. **Settlement Payment** Glenmark shall pay to the States a total of \$29,628,000.00 (the "Settlement Payment"), inclusive of interest at a rate of 8.0 percent per annum applied to \$25,000,000 of the principal, according to the following payment schedule:

| Date                            | Payment     | Principal   | Interest    | <i>Balance Remaining</i> | <i>Corporate Entity Payment</i> |
|---------------------------------|-------------|-------------|-------------|--------------------------|---------------------------------|
| 30 days of preliminary approval | \$4,387,500 | \$4,250,000 | -           | \$20,750,500             | \$137,500                       |
| 7/1/2027                        | \$6,422,500 | \$4,625,000 | \$1,660,000 | \$16,125,000             | \$137,500                       |
| 7/1/2028                        | \$5,915,000 | \$4,625,000 | \$1,290,000 | \$11,500,000             |                                 |
| 7/1/2029                        | \$6,382,500 | \$5,462,500 | \$920,000   | \$6,037,500              |                                 |

| Date     | Payment     | Principal   | Interest  | <i>Balance Remaining</i> | <i>Corporate Entity Payment</i> |
|----------|-------------|-------------|-----------|--------------------------|---------------------------------|
| 7/1/2030 | \$6,520,500 | \$6,037,500 | \$483,000 |                          |                                 |

The first installment Settlement Payment according to the above schedule shall be held in escrow by the States pending final approval of the Settlement Agreement. Each installment will be paid pursuant to the written payment instructions provided by the Attorneys General.

Glenmark warrants that, as of the Effective Date of this Agreement, it is not insolvent, nor will its Settlement or Corporate Entity Payments render it insolvent within the meaning of or for the purpose of the United States Bankruptcy Code. In the event that Glenmark fails to pay the Settlement Payment as provided in the payment schedule set forth above, Glenmark shall be in default of Glenmark's payment obligations ("Default"). The States will provide a written Notice of Default, and Glenmark shall have an opportunity to cure such Default within seven (7) calendar days from the date of receipt of the Notice of Default by making the payment due under the payment schedule and paying any additional interest accruing under the Settlement Agreement up to the date of payment. Notice of Default will be delivered to Glenmark according to the Notice provisions set forth below. If Glenmark fails to cure the Default within seven (7) calendar days of receiving the Notice of Default and in the absence of an agreement with the States to a modified payment schedule ("Uncured Default"), the remaining unpaid balance of the Settlement Amount shall become immediately due and payable, and interest on the remaining unpaid balance shall thereafter accrue at the rate of 12% per annum, compounded daily from the date of Default, on the remaining unpaid total (principal and interest balance).

In the event of Uncured Default, Glenmark agrees that the States, at their sole discretion, may (i) retain any payments previously made, rescind this Agreement or bring any civil and/or administrative claim, action, or proceeding against Glenmark for the claims that would otherwise be covered by the releases provided herein, with any recovery reduced by the amount of any payments previously made by Glenmark to the States under this Agreement; (ii) take any action to enforce this Agreement in a new action; or (iii) exercise any other right granted by law, or under the terms of this Agreement, or recognizable at common law or in equity. . The States shall be entitled to any other rights granted by law or in equity by reason of Default, including referral of this matter for private collection. In the event that the States opt to rescind this Agreement pursuant to this paragraph, Glenmark waives and agrees not to plead, argue, or otherwise raise any defenses of statute of limitations, laches, estoppel or similar theories, to any civil or administrative claims that are (i) filed by the States against Glenmark within 120 days of written notification that this Agreement has been rescinded, and (ii) relate to the Conduct, except to the extent these defenses were available as of the date of this Agreement. Glenmark agrees not to contest any offset, recoupment, confession or stipulation of judgment filed in a court of competent jurisdiction by an Attorney General signatory to this agreement, and /or collection action undertaken by the States pursuant to this paragraph, either administratively or in any state or federal court, except on the grounds of actual payment to the States.

**B. Identification of Assets and Liens.** Upon written request by the Attorneys General, Glenmark shall, within sixty (60) days of such a request, provide the Attorneys General with a confidential, comprehensive written statement that consists of identification of material assets and material liens (“Asset Information”) and shall respond to reasonable questions about the Asset Information. In the event that there is a material change in the Asset Information following the disclosure of the Asset Information, Glenmark shall, within thirty (30) days after such material change, provide the Attorneys General with an updated statement of Asset Information. Glenmark shall also make commercially reasonable efforts to notify the Attorneys General 90 days prior to any filing for bankruptcy and such notice may be used by the Attorneys General to trigger the acceleration of all remaining payments due under this Settlement Agreement, the confession of judgment, and the entry of liens. The provision of any information pursuant to this Paragraph shall be treated as Highly Confidential under the applicable Protective Orders.

**C. Settlement Payment Allocation** Seventy percent (70%) of each installment of the Settlement Payment will constitute restitution within the meaning of Section 162(f)(2) of the Code and 26 C.F.R. § 1.162-21(e)(4)(i). No part of the Settlement Payment that constitutes restitution is paid (a) in respect of any claim for the trebling of damages (as opposed to actual damages), or (b) for or in lieu of any fine, penalty, forfeiture, or punitive damages, and no part of the amount specified as restitution in the preceding sentence is paid to reimburse any Attorney General, any State Entity, or any other government or governmental entity for investigation or litigation costs. The party or parties required to report all or any portion of the Settlement Payment under Section 6050X of the Code shall report no less than 70% of such portion as restitution. Except as set forth in this Paragraph, the Attorneys General take no position on tax treatment of the payments under the Settlement.

The Settlement Payment shall be allocated among the State Entities that are State Releasors as determined by the Attorneys General. The amounts allocated to the State Entities that are State Releasors shall be received by the respective State Attorneys General Offices to be allocated for any use permitted under state law at the sole discretion of the State’s Attorney General.

The States will hold the remaining thirty percent (30%) of each installment of the Settlement Payment in escrow and for use in paying for the expenses identified in Section II C and, upon final approval of this Agreement, for costs of litigating the States’ claims both collectively or individually, subject to approval of the Court. To the extent that monies in the cost account are not used to offset costs of States litigating in the State Actions, any remaining funds may be used for any of the following: (1) Deposit into a state antitrust or consumer protection account (e.g., revolving account, trust account) for use in accordance with the laws governing the account; (2) Deposit into a fund exclusively dedicated to assisting any state to defray the costs of experts, economists and consultants in multistate antitrust investigations and litigations, including healthcare related investigations and litigation; (3) Antitrust or consumer protection enforcement, including healthcare-related enforcement, by an individual State or

multiple States; or (4) For any other use permitted by state law at the sole discretion of that State's Attorney General.

D. The Parties agree and understand that any distribution plan is to be considered by the Court separately from the Court's consideration of the fairness, reasonableness, and adequacy of the resolution set forth in the Settlement Agreement, and any order or proceedings relating to any distribution plan shall not operate to terminate or cancel the Settlement Agreement or affect the finality of the Final Approval Order, or any other orders entered pursuant to the Settlement Agreement. If the Court denies final approval of the Settlement Agreement, the full amount shall be refunded to Defendants within five (5) business days, less any amounts expended for Settlement Administration Costs not to exceed a total of \$250,000.

E. The Parties further agree and understand that Glenmark shall have no obligation to make any other payments of any kind in connection with this Agreement. Glenmark also shall have no obligations with respect to the allocation or distribution of any of the Settlement Funds. The State Releasors shall have no other recovery of any kind from the Glenmark Releasees, other than from the Settlement Payment, including for attorneys' fees, costs, service awards, damages, penalties, or injunctive or other relief of any kind.

F. **Corporate Entity Payments.** Separate from the settlement allocation described in Paragraph C of this Section and in consideration for the release of Corporate Entity claims by Idaho and Washington, Glenmark agrees to pay \$275,000 over 2 payments according to the payment schedule in the chart found in this section. These payments will be distributed to Idaho and Washington. These payments will not be subject to the interest payments described in this section. These payments will constitute restitution within the meaning of Section 162(f)(2) of the Code and 26 C.F.R. § 1.162-21(e)(4)(i). No part of the Corporate Entity Payments is paid (a) in respect of any claim for the trebling of damages (as opposed to actual damages), or (b) for or in lieu of any fine, penalty, forfeiture, or punitive damages, and no part of the amount specified as restitution in the preceding sentence is paid to reimburse any Attorney General, any State Entity, or any other government or governmental entity for investigation or litigation costs. The party or parties required to report the Corporate Entity Payment under Section 6050X of the Code shall report such payments as restitution. Except as set forth in this Paragraph, the Attorneys General take no position on tax treatment of the payments under the Settlement.

#### IV. RELEASED AND RESOLVED CLAIMS

A. The States release the Glenmark Releasees from all claims that the States brought or could have brought against the Glenmark Releasees (except on behalf of Local Entities and on behalf of Eligible Consumers) in the Actions brought by States relating to the drugs specified in the Actions based on the Conduct as alleged, namely, antitrust, consumer protection, fraud or false claims act, "overarching conspiracy," unjust enrichment and disgorgement claims. The States covenant not to sue the Glenmark Releasees for all claims that the States brought or could have brought against other defendants for any other drug for which the States assert a claim in any of the States' Actions based on the Conduct alleged in the States' Actions. Released Claims include, but are not limited to, claims arising out of the Conduct under (1) federal or state



antitrust laws, (2) unfair competition or consumer protection laws, (3) any civil or administrative monetary cause of action (including for civil damages and/or civil fines or penalties), (4) any remedies for any claims submitted or caused to be submitted to the State's Medicaid program, including under the False Claims Act (codified at 31 U.S.C. §§ 3729-3733) or any State's counterpart to the federal False Claims Act, and (5) any other statute or common or equitable law. The claims released and the claims on which the States covenant not to sue are collectively referred to as "Released and Resolved Claims."

B. As permitted by law, each State fully and finally releases and forever discharges the Glenmark Releasees from all Released and Resolved Claims. Each State hereby covenants and agrees that it shall not sue or otherwise seek to establish or impose liability, in any capacity and on behalf of itself or any other person or entity or class thereof, against the Glenmark Releasees based, in whole or in part, on any of the Released and Resolved Claims.

C. Notwithstanding any term in this Settlement Agreement, Released and Resolved Claims specifically do not include claims unrelated to the alleged Conduct, including:

1. Any civil or administrative liability under state revenue codes;
2. Any civil or administrative liability related to a State's Medicaid program under any statute, regulation, or rule for any conduct unrelated to the Conduct alleged in the States' complaints, including, but not limited to, state or federal false claims act, anti-kickback or off-label marketing violations for the specified drugs;
3. Exclusion from a State's Medicaid program as prescribed by federal or state law
4. Any criminal liability unrelated to alleged antitrust or related violations;
5. Any breach of contract or any liability for expressed or implied warranty claims or other liability for defective or deficient products and services provided by Defendants;
6. Any liability for unfair or deceptive representations made in the marketing or advertising or for off-label marketing claims for the specified drugs to the extent that such claims are not predicated on the Conduct alleged in the Action;
7. Any securities-based liability;
8. Any claim by a corporate (and other business) entities for whom the Attorney General of Illinois has asserted a claim in the Actions; and
9. Any claim arising from obligations under this Agreement.

D. In addition, the State Releasors, with the exception of Arizona and New Mexico, expressly waive, release, and forever discharge any and all provisions, rights, and benefits conferred by § 1542 of the California Civil Code, which reads:

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor or released party.

The State Releasors further expressly waive any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or other jurisdiction, or principle of common law, which is similar, comparable or equivalent to § 1542 of the California Civil Code.

E. The Parties may discover facts other than or different from what the Party believes to be true with respect to price-fixing, market allocation, or bid-rigging within the time periods mentioned in the States' complaints filed by the States in the States' Actions in the MDL concerning the Released and Resolved Claims, but each Party expressly waives and fully, finally and forever settles, releases, resolves, and discharges, upon this Settlement Agreement becoming final, any suspected or unsuspected, asserted or unasserted, contingent or non-contingent claim that would otherwise fall within the definition of Released and Resolved Claims, whether or not concealed or hidden, without regard to the subsequent discovery or existence of such different or additional facts. This provision shall not in any way expand the scope of the Released and Resolved Claims and shall not convert what is a limited release into a general release.

F. **Preservation of Claims against Other Defendants.** Glenmark's sales of drugs specified in the State Actions shall, to the extent permitted or authorized by law, remain in the State Actions against other defendants in the Action as a potential basis for restitution and other monetary claims and shall be asserted as a part of any joint and several liability claims against other defendants in the State Actions or against other persons other than the Glenmark Releasees.

G. **Preservation of Claims Held by Eligible Consumers.** This Agreement shall not preclude any claim other than the Released Claims and will not bar any claim or claims brought by any other person or party, including without limitation all claims asserted in any private suit or class action now pending against the Defendant, including the Eligible Consumers' claims, which have been expressly reserved and not released.

H. **Resolution of State Claims Brought on Behalf of Eligible Consumers.** To the extent the States brought claims on behalf of eligible consumers, the States stipulate they will not continue, commence, or otherwise pursue litigation or any other proceedings against the Released Parties asserting or seeking remedies based on the Released Claims on behalf of Eligible Consumers. The States retain the right to reinstate these claims in bankruptcy if Defendant does not pay the full Settlement Payment as required under this agreement and Defendant files for bankruptcy.

## V. PRELIMINARY AND FINAL COURT APPROVAL

A. The Attorneys General shall promptly (and in no event more than thirty (30) calendar days after the Effective Date) file a motion(s) for a Preliminary Approval Order,



including their respective proposed notice and notice plan to inform those Consumers and Corporate Entities on whose behalf the Attorneys General have asserted claims, and anyone else for whom notice is required, of their right (i) to object to this Agreement or (ii) to file a timely and valid request for exclusion.

B. In the event that the court fails to give preliminary approval to this Agreement, then the Parties shall in good faith seek to agree on revisions to this Agreement that would remedy any issues preventing preliminary approval while retaining the spirit of the Agreement. If they are unable to agree on such revisions despite their good faith efforts, they shall each have the option to rescind this Agreement.

C. Within sixty (60) calendar days of the Preliminary Approval Order and the court's approval of the allocation plans, notice(s) and notice plan(s) submitted by the Attorneys General to the court, or such other time as directed by the court, the Attorneys General shall implement their notice plan(s), providing those Eligible Consumers and Corporate Entities for whom the Attorneys General have asserted claims, and anyone else for whom notice is required notice of their rights (i) to object to this Agreement or (ii) to file a timely and valid request for exclusion.

D. Eligible Consumers and Corporate Entities for whom the Attorneys General have asserted claims shall be given notice as required by applicable law. Costs for the notice will be paid from the State Escrow, and shall be limited to \$500,000.

E. Within thirty (30) calendar days following the conclusion of the Notice Period or as otherwise agreed by the Parties or directed by the court(s), the Attorneys General shall file with the court a Motion for a Final Approval Order. At least seven (7) calendar days prior to filing their Motion for a Final Approval Order, the Attorneys General shall provide a copy of such motion (including all exhibits and attachments to such motion) to Glenmark for review.

## **VI. EXCLUSIONS**

A. Subject to court approval, any Eligible Consumer or Corporate Entity may seek to be excluded from the Settlement by submitting a valid and timely request for exclusion. The Attorneys General, State Entities identified on Appendix B, and other State Entities that accept a distribution of settlement proceeds from the Attorneys General's settlements in the Actions, are bound by this Agreement upon execution and have no right to seek exclusion. Any Eligible Consumer or Corporate Entity that submits a valid and timely request for exclusion will not be eligible to receive a distribution of any portion of the Settlement Payment and will have no rights with respect to the Settlement. Glenmark reserves all legal rights and defenses as to all such persons or entities that submit a valid and timely request for exclusion, and nothing in this Agreement shall be used against Glenmark in any proceeding involving such persons or entities.

B. Subject to court approval, in any written request for exclusion from the Settlement, the Eligible Consumer or Corporate Entity seeking exclusion must state his, her, or its full name, address, telephone number and e-mail address and include a statement that he, she, or it wishes to be excluded from the Settlement.

C. Subject to court approval, a request for exclusion that does not comply with all of the provisions set forth in the applicable notice will be invalid, and the person or entity serving such an invalid request shall be bound by this Agreement.

D. The Attorneys General shall, within ten (10) calendar days of the deadline for submitting a request for exclusion (the “Opt-Out Deadline”), provide Glenmark with a list of, and copies of, all requests for exclusion. The Attorneys General shall file with their Motion(s) for Final Approval a list of all persons and entities that timely and validly requested exclusion.

E. Any of the Parties may dispute an exclusion request, in which case they shall, if possible, seek to resolve the disputed exclusion request by agreement within thirty (30) calendar days of the Opt-Out Deadline. If necessary, the Parties will seek court approval of any such resolutions. If the Parties are unable to resolve any such disputes, the Parties will submit such unresolved disputes to the court for decision.

## **VII. LEGAL COMPLIANCE & INJUNCTIVE RELIEF**

A. Glenmark covenants, that, during the Enforcement Period, it, along with its current directors, officers, and employees shall not, directly or indirectly, maintain, solicit, suggest, advocate, discuss or carry out any unlawful agreement with any actual or potential competitor in the generic pharmaceutical industry to: (a) fix prices for generic pharmaceuticals; (b) submit courtesy, cover, or otherwise non-competitive, bids or proposals for the supply, distribution or sale of generic pharmaceuticals; (c) refrain from bidding on, or submitting proposals for, the supply, distribution, or sale of generic pharmaceuticals; or (d) allocate customers for the sale of generic pharmaceuticals.

B. Glenmark further covenants that it shall continue to maintain, during the Enforcement Period, its existing antitrust compliance program, as described to the Attorneys General prior to entering into this Agreement. As part of its compliance program, Glenmark will continue to conduct during the Enforcement Period, periodic antitrust training sessions for its employees at least once per year. Such antitrust training has been and will continue to be delivered by an attorney with relevant experience in the field of antitrust law, and Glenmark has and will continue to monitor attendance to ensure that all employees receive the training.

C. Glenmark further covenants that it will continue to maintain, during the Enforcement Period, a Chief Compliance Officer, who serves to enforce Glenmark’s antitrust compliance program and monitor Glenmark’s employees to ensure that there are no further violations of the antitrust laws during the Enforcement Period.

D. If Glenmark’s General Counsel or Chief Compliance Officer determines a potential violation of the covenants in this Section of this Agreement has occurred, Glenmark shall take appropriate action to: (a) immediately terminate or modify Glenmark’s conduct to assure continued compliance with this Settlement Agreement (if necessary); and (b) within thirty (30) business days of such determination, provide to the designated representative of the Attorneys General, in writing, a description of the actual or potential violation of this Settlement

Agreement and the corrective actions taken (if any).

The Parties agree that the covenants above are material to and shall be enforceable upon entry of the Settlement Agreement. The covenants shall further be implemented as part of the District Court's approval of the Settlement Agreement and shall be fully enforceable thereafter as part of the District Court's approval orders for the remaining duration of these covenants. The Parties also specifically agree that the States may file a new action based on a violation of these covenants.

### **VIII. DISCOVERY, AUTHENTICATION, AND COOPERATION**

A. As of the Effective Date, continuing unless this Agreement is terminated as provided herein, the Attorneys General will not serve any discovery requests on Glenmark, take depositions of Glenmark, file any motions against Glenmark, or take any other adverse action against Glenmark in the Actions or any related litigation except to enforce the terms of this Agreement. Likewise, as of the Effective Date, continuing unless this Agreement is terminated as provided herein, Glenmark shall not serve any discovery requests on the Attorneys General, take depositions of the Attorneys General, file any motions against the Attorneys General, or take any other adverse action against the Attorneys General in the Actions or any related litigation except to enforce the terms of this Agreement. For the avoidance of doubt, the Attorneys General may continue to attend depositions of current and former Glenmark employees and may question those employees as it relates to the prosecution of claims against the non-Glenmark Defendants. Counsel for Glenmark may likewise continue to attend depositions of current and former employees of the Attorneys General, and of any other individuals represented by the Attorneys General, and may question those individuals as it relates to Glenmark's defense of claims brought by plaintiffs in the MDL or other litigation involving the same alleged Conduct as the State Actions.

B. The Attorneys General shall continue to have the same rights that they currently have to receive discovery provided by Glenmark to parties in the MDL pursuant to the protective order governing the use of documents and other information produced in the MDL, as well as the orders in the State Actions. In addition, Glenmark will use reasonable efforts to provide information necessary to authenticate and admit up to 150 documents produced by Glenmark, by affidavit if permitted by the court and by witness testimony at trial if necessary.

C. Similarly, Glenmark shall continue to have the same rights that it currently has to receive discovery provided by the Attorneys General to other parties in the State Actions pursuant to the applicable protective order governing the use of documents and other information. In addition, the Attorneys General shall use reasonable efforts to provide information necessary to authenticate up to 150 documents produced by the Attorneys General, by affidavit if permitted by the court and by witness testimony at trial if necessary.

D. In addition to the above, Glenmark agrees to provide cooperation to the Attorneys General as set forth in Appendix C. All such cooperation shall be treated by the Attorneys General as "highly confidential" and not disclosed to any other party in the Actions, the MDL, or

any related proceedings.

E. Glenmark will also in good faith consider reasonable requests from the Attorneys General for additional assistance that does not impose an undue burden on Glenmark. The Attorneys General will likewise in good faith consider reasonable requests from Glenmark for additional assistance that does not impose an undue burden on Glenmark.

F. Glenmark shall not be required to produce any documents or otherwise disclose information protected by the work product doctrine, attorney-client privilege, common-interest privilege, joint-defense privilege, or any other applicable doctrine or privilege; or disclosure of which is prohibited by any relevant law (including foreign laws), government entities, or court order.

## **IX. QUALIFIED SETTLEMENT FUND**

A. The “State Escrow” (a “Settlement Fund”) will be established by order of the District Court at Huntington Bank with such bank serving as escrow agent (“Escrow Agent”) subject to one or more escrow agreements mutually acceptable to the Parties. Each Settlement Fund is established to resolve and satisfy one or more claims described in the preamble to this Settlement Agreement, and each shall be subject to the District Court’s continuing supervision and control. In addition, the Attorneys General shall make such elections as necessary or advisable to carry out the provisions of this Section. Such elections shall be made in compliance with the procedures and requirements contained in any applicable regulations.

B. The Parties intend that the Settlement Fund shall be a “qualified settlement fund” within the meaning of Treasury Regulation § 1.468B-1, shall act in a manner consistent with the treatment of the Settlement Fund as such a qualified settlement fund, and shall not take a position in any filing or before any tax authority that is inconsistent with such treatment. All provisions of this Settlement Agreement shall be interpreted in a manner that is consistent with the Settlement Fund being a “qualified settlement fund” within the meaning of Treasury Regulation § 1.468B-1. The administrators for the State Escrow shall be California, New York and Ohio (each, in such capacity, an “Administrator”). The Administrator shall cause the timely and proper filing of all informational and other tax returns necessary or advisable with respect to the applicable Settlement Fund (including without limitation the returns described in Treasury Regulation §§ 1.468B-2(k)(1) and (l)(2)). The Administrator shall make a “relation-back election” (as defined in Treasury Regulation § 1.468B-1(j)), if available, to permit the Settlement Fund to be treated as a qualified settlement fund from the earliest permitted date. It shall be the responsibility of the Administrator to cause the timely and proper preparation and delivery of the necessary documentation with respect to the Settlement Fund for signature by all necessary parties, and thereafter to cause the appropriate filing to occur.

C. The Escrow Agent shall cause the Settlement Fund to be invested in short-term instruments backed by the full faith and credit of the United States Government or fully insured in writing by the United States Government, or money market funds rated Aaa and AAA, respectively, by Moody’s Investor Services and Standard and Poor’s, invested substantially in

such instruments, and shall reinvest any income from these instruments and the proceeds of these instruments as they mature in similar instruments at their then current market rates. The Released Parties shall bear no risk related to the Settlement Fund. The Settlement Fund shall be deemed and considered to be in custodia legis of the District Court and shall remain subject to the jurisdiction of the District Court, until such time as the funds therein shall be distributed pursuant to this Settlement Agreement or further order(s) of the District Court.

D. All (i) taxes (including any estimated taxes, interest, or penalties) arising with respect to the income earned on a Settlement Fund, including any taxes or tax detriments that may be imposed upon any Released Party with respect to income earned on a Settlement Fund for any period during which such Settlement Fund does not qualify as a qualified settlement fund for federal or state income tax purposes (“Taxes”); and (ii) expenses and costs incurred in connection with the operation and implementation of a Settlement Fund (including expenses of tax attorneys and/or accountants and mailing and distribution costs and expenses relating to filing (or failing to file) tax returns with respect to the Settlement Fund (“Tax Expenses”)), shall be paid out of such Settlement Fund.

E. Neither Glenmark nor any Glenmark Releasee nor their respective counsel shall have any liability or responsibility with respect to a Settlement Fund for the Taxes or the Tax Expenses or the filing of any tax returns or other documents with the Internal Revenue Service or any other taxing authority. The Escrow Agent and Attorneys General respectively shall indemnify and hold the Released Parties harmless for Taxes and Tax Expenses (including taxes payable by reason of such indemnification). Further, Taxes and Tax Expenses shall be treated as, and considered to be, a cost of administration of the Settlement Fund and shall be timely paid by the Administrator out of the Settlement Fund without prior order from the District Court and the Administrator shall be obliged (notwithstanding anything herein to the contrary) to withhold from distribution to any claimants authorized by the District Court any funds necessary to pay such amounts including the establishment of adequate reserves for any Taxes and Tax Expenses (as well as any amounts that may be required to be withheld under Treasury Regulation § 1.468B-2(l)(2)). No Releasee shall be responsible or have any liability therefore or for any reporting requirements that may relate thereto. The Parties agree to cooperate with each other and their tax attorneys and accountants to the extent reasonably necessary to carry out the provisions of this Section.

## **X. THE SETTLEMENT FUNDS**

A. State Releasors shall look solely to the Settlement Funds for settlement and satisfaction against the Glenmark Releasees of all Released and Resolved Claims and shall have no other recovery against Glenmark or any of the Glenmark Releasees for any Released Claims.

B. After this Agreement receives Final Court Approval, and at a time to be determined the Attorneys General, respectively, the Settlement Funds shall be distributed in accordance with the plans to be submitted, subject to approval by the court. In no event shall Glenmark or any Glenmark Releasee have any responsibility, financial obligation, or liability whatsoever with respect to the investment or distribution of the Settlement Funds, or the

administration of the Settlement Funds, including the costs and expenses of such investment, distribution and administration.

## **XI. RESCISSION IF AGREEMENT IS NOT APPROVED OR FINAL JUDGMENT IS NOT ENTERED**

A. In the event that the court fails to grant Final Court Approval to this Agreement, then the Parties shall in good faith seek to agree on revisions to this Agreement that would remedy any issues preventing Final Court Approval while retaining the spirit of the Agreement. If they are unable to come to agreement on such revisions, despite their good faith efforts, they shall each have the option to rescind this Agreement.

B. Written notice of the exercise of any right to rescind provided for under this Section XI shall be made according to the terms herein.

C. In the event that this Agreement does not receive Final Court Approval, or this Agreement otherwise is terminated or rescinded by any party under any provision herein, then: (i) this Agreement shall be of no force or effect, except as expressly provided in Paragraphs XI.A. and XI.B. or other portions of this Agreement; (ii) the Settlement Funds (with any interest accrued thereon) shall be returned forthwith to Glenmark less only disbursements made in accordance with Section IX and Paragraph III.C. of this Agreement; and (iii) Glenmark shall be entitled to any tax refunds owing to the Settlement Funds. At the request of Glenmark, and at Glenmark's expense, the Attorneys General shall cause to be filed claims for any tax refunds owed to the Settlement Funds and pay the proceeds, after deduction of any fees and expenses incurred with filing such claims for tax refunds, to Glenmark. All expressly reserve all of their rights, claims and defenses if this Agreement does not receive Final Court Approval or is otherwise terminated or rescinded.

D. Further, and in any event, Glenmark and the Attorneys General agree that this Agreement, whether or not it receives Final Court Approval or is otherwise terminated or rescinded by any Party under any provision herein, and any and all negotiations, documents, and discussions associated with it, shall not be deemed or construed to be an admission or evidence of (i) any violation of any statute or law or of any liability or wrongdoing whatsoever by Glenmark or any other Glenmark Releasees, or (ii) the truth of any of the claims or allegations contained in the Actions or any other pleading filed in the MDL or any court to which any State Actions have been or may be remanded. Evidence derived from this Agreement, and any and all negotiations, documents, and discussions associated with it shall not be discoverable or used in any way, whether in the Actions or in any other action or proceeding, against Glenmark or other Glenmark Releasees (except to enforce this Agreement).

## **XII. NOTICE**

A. Notice to Glenmark pursuant to this Settlement Agreement shall be sent by registered United States mail, return receipt requested, and electronic mail to:



Dimitra Doufekias  
Rob Manoso  
Morrison Foerster LLP  
2100 L Street NW, Suite 900  
Washington, DC 20037  
202-887-1553  
[ddoufekias@mofo.com](mailto:ddoufekias@mofo.com)  
[rmanoso@mofo.com](mailto:rmanoso@mofo.com)

B. Notice to Attorneys General pursuant to this Settlement Agreement shall be sent by registered United States mail return receipt requested and electronic mail, including to Lead Counsel:

Christopher Teters  
Assistant Attorney General, Public Protection Division  
Office of Kansas  
Attorney General Kris Kobach  
120 SW 10th Avenue, 2nd Floor  
Topeka, Kansas 66612  
(785) 296-3751  
[chris.teters@ag.ks.gov](mailto:chris.teters@ag.ks.gov)

Nicole Demers  
Deputy Associate Attorney General  
Office of the Connecticut Attorney General  
165 Capitol Ave.,  
Hartford, CT 06106  
(860) 808-5030  
[nicole.demers@ct.gov](mailto:nicole.demers@ct.gov)

### **XIII. MISCELLANEOUS**

A. This Agreement shall not be deemed or construed to be an admission of liability or of any violation of any statute or law or of any wrongdoing by the Glenmark Releasees. Nor shall this Agreement be deemed as an admission by the Glenmark Releasees of any of the allegations or claims by the Attorneys General. Nor shall the Agreement be used as an admission as to the strength or weakness of any party's claims or defenses. This Agreement may not be used by the Attorneys General or anyone else in any pending or future civil, criminal, or administrative action or proceeding against the Glenmark Releasees, except in a proceeding or action to enforce this Agreement.

B. This Agreement may be executed in counterparts, each of which will be deemed an original, but which together will constitute one and the same instrument, and a facsimile signature or PDF signature shall be deemed an original signature for purposes of executing this Agreement. In addition, the state Medicaid agencies listed on Appendix B will sign on a separate



form, unless otherwise agreed-to in writing by Glenmark.

C. This Agreement, together with the confidential understandings identified herein, contains the entire Agreement between the parties, and no other understandings or agreements, verbal or otherwise, exist between the parties, except as set forth or referred to herein.


D. This Agreement (other than the Cooperation Agreement, which is governed by its own terms) may not be modified, changed, cancelled, rescinded, amended, or varied (except under the specific termination provisions set forth herein), nor may any or all of its terms be waived, except by a writing signed by all of the parties.

E. None of the parties to this Agreement shall be considered to be the drafter of this Agreement or any of its provisions for the purpose of any statute, case law, or rule of interpretation or construction that would or might cause any provision to be construed against the drafter of this Agreement.

F. Where this Agreement requires either party to provide notice or any other communication or document to the other, such notice shall be in writing and shall be provided as set forth in Section XII.

G. This Agreement shall be governed by, construed by, and enforced in accordance with the laws of the State of Connecticut, including Conn. Gen. Stat. Ann. § 52-572h, barring contribution against a settling defendant. In addition, the law of each state (including, e.g., Cal. Civ. Pro. Code § 877 and N.Y. Gen. Oblig. Law § 15-108) continues to apply with respect to all settlements entered into and judgments entered in connection with claims related to the Conduct and based on that state's law. Consistent with such law, this Agreement is conditioned upon the court's finding that it was entered into in good faith. In addition, Glenmark has entered into supplemental agreements with certain States (Delaware, Georgia, Idaho, Maryland, Mississippi, New Mexico, Pennsylvania, and South Dakota) that provide additional obligations concerning claims for contribution. The parties agree that venue for any and all matters or disputes arising out of this Agreement shall lie in the U.S. District Court for the District of Connecticut.

H. Each party affirms that this Agreement has been executed by its authorized representative, who is acting within his or her capacity and authority and that by his or her signature this representative is binding the Party on behalf of whom the Agreement is executed to the terms and conditions of this Agreement.

A handwritten signature in black ink, appearing to read 'Dimitra Doufekias', is written over a horizontal line.

Dimitra Doufekias  
Morrison & Foerster LLP  
2100 L Street NW, Suite 900  
Washington, DC 20037  
(202) 887-1553  
ddoufekias@mofo.com  
*Attorney for Defendant Glenmark  
Pharmaceuticals Inc. USA*

Dated: May 22, 2026

CORI MILLS  
ACTING ATTORNEY GENERAL

/s/ Jeff Pickett

By: Jeff Pickett

Senior Assistant Attorney General

AK Bar No. 9906022

State of Alaska, Department of Law

1031 W. 4<sup>th</sup> Ave., Suite 200

Anchorage, AK 99501

Tel: (907) 269-5275

[jeff.pickett@alaska.gov](mailto:jeff.pickett@alaska.gov)

*Attorney for State of Alaska*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND  
THE SINGLE STATE AGENCY FOR  
ALASKA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Alaska (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 2/17/2026

Signature: 

Name: Heather Nobrega

Position/Title: Assistant Attorney General

Director, Alaska Medicaid Fraud Control Unit

**Single State Agency for Medicaid**

Dated: 03/02/2026

Signature:



Name:

Emily Ricci

Position/Title:

Deputy Commissioner/Medicaid Director

**KRISTIN K. MAYES**  
**Attorney General**

By: /s/ Robert A. Bernheim  
Robert A. Bernheim  
Unit Chief Counsel, Antitrust & Privacy Unit  
Office of the Arizona Attorney General  
400 W. Congress, Ste. S-315  
Tucson, AZ 85701  
Telephone: (520) 628-6507  
Facsimile: (602) 542-4377

*Counsel for State of Arizona*

Dated: June 4, 2026

/s/ Emilio Varanini

Emilio Varanini  
Supervising Deputy Attorney General  
Office of the Attorney General California  
455 Golden Gate, Suite 11000  
San Francisco, CA 94102-7004  
Telephone: (415) 510-3541  
E-mail: [Emilio.Varanini@doj.ca.gov](mailto:Emilio.Varanini@doj.ca.gov)

*Attorney for the State of California*

Dated: June 29, 2026



**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
CALIFORNIA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of California (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: Feb.24, 2026

  
\_\_\_\_\_  
Randal L. Glaser  
Supervising Deputy Attorney General  
Division of Medi-Cal Fraud and Elder Abuse  
California Department of Justice

**Single State Agency for Medicaid**

Dated: \_\_\_\_\_ Signature: \_\_\_\_\_  
Name: \_\_\_\_\_  
Position/Title: \_\_\_\_\_  
\_\_\_\_\_

**FOR PLAINTIFF STATE OF COLORADO  
PHILIP J. WEISER  
ATTORNEY GENERAL**

/s/ Robin Alexander

Robin Alexander  
Assistant Attorney General  
Colorado Department of Law  
1300 Broadway, 10th Floor  
Denver, CO 80203  
Telephone: (720) 508-6000  
Robin.Alexander@coag.gov

*Counsel for the Plaintiff State of Colorado*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND  
THE SINGLE STATE AGENCY FOR  
COLORADO**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Colorado (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 03/05/2026

Signature:

**Rebecca Weber**

Digitally signed by Rebecca  
Weber

Date: 2026.03.05 13:14:47 -07'00'

Name:

Rebecca Weber

Position/Title:

First Assistant Attorney General/Director

Colorado Medicaid Fraud, Abuse & Neglect Unit

**Single State Agency for Medicaid**

Dated: 03/02/2026

Signature: 

Name: Kim Bimestefer

Position/Title: Executive Director

/s/ Amy Taylor

Amy Taylor (phv209197)

Assistant Attorney General

Nicole Demers

Deputy Associate Attorney General

Federal Bar No. ct27223

Connecticut Office of the Attorney General

165 Capitol Ave.

Hartford, CT 06106

Tel: (860) 808-5030

Fax: (860) 808-5391

[Amy.Taylor@ct.gov](mailto:Amy.Taylor@ct.gov)

[Nicole.Demers@ct.gov](mailto:Nicole.Demers@ct.gov)

*Counsel for the State of Connecticut*

Dated: May 21, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
CONNECTICUT**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Connecticut (the "State") regarding the Settlement Agreement:


**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 2/17/2026

Signature: 

Name:

Marjorie Sozanski

Position/Title:

Supervisory Assistant State's Attorney

Director of the Connecticut Medicaid Fraud Control  
Unit

**Single State Agency for Medicaid**

John

Jakubowski

Digitally signed by John Jakubowski  
DN: cn=John Jakubowski,  
o=Department of Social Services,  
ou=Quality Assurance,  
email=john.jakubowski@ct.gov, c=US  
Date: 2026.02.19 11:24:59 -05'00'

Dated: 2/18/26

Signature:


Name:

John Jakubowski

Position/Title:

Director of Quality Assurance - DSS





Adam Gitlin  
Chief, Antitrust and Nonprofit  
Enforcement Section  
400 6th St. NW, 9th Fl.  
Washington, DC 20001  
Tel: (202) 442-9864  
Adam.Gitlin@dc.gov

*Counsel for District of Columbia*

Dated: 2/23/2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
THE DISTRICT OF COLUMBIA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the District of Columbia (District) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the District have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the District and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/5/2026

Signature: LaVan Griffith

Name: LaVan Griffith

Position/Title: Assistant Inspector General-Director, MFCU

**Single State Agency for Medicaid**

Dated: 3/5/26

Signature: 

Name: Sheryl Johnson

Position/Title: General Counsel DHCF

A handwritten signature in blue ink, appearing to read "Michael A. Undorf", is positioned above a horizontal line.

Michael A. Undorf  
Deputy Attorney General  
Delaware Department of Justice  
820 N. French St., 5<sup>th</sup> Floor  
Wilmington, DE 19801  
(302) 683-8816  
michael.undorf@delaware.gov

*Counsel for the State of Delaware*

Dated: May 20, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
DELAWARE**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Delaware (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 2/16/26

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Position/Title: \_\_\_\_\_

*[Handwritten Signature]*  
\_\_\_\_\_  
*Stephen McDermott*  
\_\_\_\_\_  
*Director, Medicaid Fraud Control Unit*  
\_\_\_\_\_  
*Delaware Department of Justice*  
\_\_\_\_\_

**Single State Agency for Medicaid**

Dated: 3/9/2026 \_\_\_\_\_

Signature: \_\_\_\_\_

DocuSigned by:

*Andrew Wilson*

35F947C98C8B499...

Name: \_\_\_\_\_

Andrew Wilson

Position/Title: \_\_\_\_\_

Director

JAMES UTHMEIER  
Attorney General  
State of Florida

By: /s/ Lizabeth A. Brady  
Lizabeth A. Brady  
Director, Antitrust Division  
Timothy Fraser  
Special Counsel  
PL-01, The Capitol  
Tallahassee, FL 32399-1050  
Telephone: (850) 414-3300  
Facsimile: (850) 488-9134

*Counsel for State of Florida*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
FLORIDA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Florida (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 5/26/26

Signature: \_\_\_\_\_



Name: \_\_\_\_\_

Ryan Newman

Position/Title: \_\_\_\_\_

Chief Deputy Attorney General

State of Florida



**Single State Agency for Medicaid**

Dated: 5/22/2026

Signature:



Name:

Brian Meyer

Position/Title:

Deputy Secretary for Medicaid

Florida Agency for Health Care Administration

STATE OF GEORGIA

/s/ Logan Winkles

Christopher Carr, Attorney General  
Logan Winkles, Deputy Attorney General  
Ron Stay, Sr. Asst. Attorney General  
Charles Thimmesch, Sr. Asst. Attorney General  
Office of the Georgia Attorney General  
40 Capitol Sq. SW  
Atlanta, GA 30334  
(404) 458-3626  
cthimmesch@law.ga.gov

*Attorneys for the State of Georgia*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
Georgia**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Georgia (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/2/2026

Signature: 

Name: Jim Mooney

Director, Medicaid Fraud and Patient Protection Division

Georgia Department of Law

Position/Title:

**Single State Agency for Medicaid**

Dated: 2/27/2026

Signature: *Melanie Simon*

Name: Melanie Simon

Position/Title: General Counsel

Georgia Department of Community Health

PLAINTIFF STATE OF IDAHO  
RAÚL R. LABRADOR  
ATTORNEY GENERAL

By: /s/ John K. Olson

John K. Olson  
Deputy Attorney General  
Idaho Office of the Attorney General  
Consumer Protection Division  
954 West Jefferson Street, 2<sup>nd</sup> Floor  
Boise, Idaho 83702  
(208) 332-3549  
[john.olson@ag.idaho.gov](mailto:john.olson@ag.idaho.gov)

*Counsel for the State of Idaho*

Dated: May 22, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
IDAHO**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Idaho (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: **03/04/2026**

Signature: 

Name: Ashley Klenski

Position/Title: Director, Medicaid Fraud Control Unit

Office of Idaho Attorney General

**Single State Agency for Medicaid**

Dated: 2/27/26

Signature: \_\_\_\_\_

Name: Sasha O'Connell

Position/Title: Deputy Director, Division of Medicaid

Idaho Department of Health and Welfare

**FOR PLAINTIFF STATE OF ILLINOIS  
KWAME RAOUL  
ATTORNEY GENERAL**

/s/ Brian M. Yost

Brian M. Yost

Supervising Attorney

Office of the Illinois Attorney General

115 S. LaSalle St.

Chicago, Illinois 60603

Tel: (872) 276-3598

Brian.Yost@ilag.gov

*Counsel for the Plaintiff State of Illinois*



**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
ILLINOIS**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Illinois (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/9/26

Signature: Heather D'Orazio

Name: Heather D'Orazio

Position/Title: Director, IL MFCU

**Single State Agency for Medicaid**

Dated: 3/6/2026

Signature: Elizabeth M. Whitehorn by Cassidy Jeon

Name: Elizabeth M. Whitehorn

Position/Title: Director, IL Department of Healthcare and Family Services

*In re Generic Pharmaceuticals Pricing Antitrust Litigation*, MDL No. 2724 (E.D. Pa.)  
**Glenmark-1302**

PLAINTIFF STATE OF INDIANA

THEODORE E. ROKITA  
INDIANA ATTORNEY GENERAL

By: /s/ Tamara Weaver

Tamara Weaver

Deputy Attorney General

Indiana Government Center South – 5th Fl.

302 W. Washington Street

Indianapolis, IN 46204-2770

Phone: (317) 234-7122

Fax: (317) 232-7979

Email: [Tamara.Weaver@atg.in.gov](mailto:Tamara.Weaver@atg.in.gov)

*Counsel for Plaintiff State of Indiana*

Dated: March 23, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
INDIANA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Indiana (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated:  
\_\_5.19.2026\_\_

Signature: Matthew Whitmire

Name: Matthew G. Whitmire

Position/Title: MFCU Director & Chief Counsel

Office of the Indiana Attorney General

**Single State Agency for Medicaid**

Dated: \_\_05.19.26\_\_

Signature: 

Name: Audrey Frenzel

Position/Title: Director of Medicaid

Indiana Family and Social Services Administration

/s/ Noah Goerlitz

Noah Goerlitz

Assistant Attorney General

Office of the Iowa Attorney General

1305 E. Walnut St.

Des Moines, IA 50319

(515) 725-1018

noah.goerlitz@ag.iowa.gov

*Counsel for the State of Iowa*

Dated: February 19, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
IOWA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Iowa (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 02/23/2026

Signature: 

Name: Tricia Dieleman

Position/Title: Assistant Attorney General for the Iowa MFCU

Iowa Attorney General's Office & Medicaid Fraud  
Control Unit

**Single State Agency for Medicaid**

Dated: 02/20/2026

Signature:



---

Name: Lee Grossman

Position/Title: Medicaid Director

Iowa Health and Human Services

/s/Christopher Teters

Christopher Teters, KS No. 27248

Assistant Attorney General

Office of the Kansas Attorney General, Kris. W. Kobach

120 SW 10th. Ave., Fl. 2,

Topeka, KS 66612

(785) 368-8429

chris.teters@ag.ks.gov

*Counsel for the State of Kansas*

Dated: June 9, 2026



**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR KANSAS**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Kansas (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc.* et al, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

**Signature:** *Gregory T. Benefiel*

**Email:** Greg.Benefiel@ag.ks.gov

Gregory T. Benefiel, Director  
Medicaid Fraud and Abuse Division  
Office of the Kansas Attorney General  
120 SW 10<sup>th</sup> Avenue  
Topeka, Kansas 66612

**Single State Agency for Medicaid**

**Signature:** *Shon D. Qualseth*  
Shon D. Qualseth (Mar 5, 2026 10:19:12 CST)

**Email:** shon.qualseth@ks.gov

Shon D. Qualseth, General Counsel  
Kansas Dept. of Health & Environment  
1000 SW Jackson, Suite 560  
Topeka, Kansas 66612

# MFCU and SSA Signature Page -- Glenmark-1302 FINAL

Final Audit Report

2026-03-05

|                 |                                              |
|-----------------|----------------------------------------------|
| Created:        | 2026-03-02                                   |
| By:             | Greg Benefiel (Greg.Benefiel@ag.ks.gov)      |
| Status:         | Signed                                       |
| Transaction ID: | CBJCHBCAABAAN9WXHyr7AOcnY2jbYoBIVMimF50JesJ7 |

## "MFCU and SSA Signature Page -- Glenmark-1302 FINAL" History

 Document created by Greg Benefiel (Greg.Benefiel@ag.ks.gov)  
2026-03-02 - 8:59:04 PM GMT

 Document e-signed by Greg Benefiel (Greg.Benefiel@ag.ks.gov)  
Signature Date: 2026-03-02 - 9:01:57 PM GMT - Time Source: server

 Document emailed to shon.qualseth@ks.gov for signature  
2026-03-02 - 9:02:00 PM GMT

 Email viewed by shon.qualseth@ks.gov  
2026-03-05 - 4:18:16 PM GMT

 Signer shon.qualseth@ks.gov entered name at signing as Shon D. Qualseth  
2026-03-05 - 4:19:10 PM GMT

 Document e-signed by Shon D. Qualseth (shon.qualseth@ks.gov)  
Signature Date: 2026-03-05 - 4:19:12 PM GMT - Time Source: server

 Agreement completed.  
2026-03-05 - 4:19:12 PM GMT



**Adobe Acrobat Sign**

Commonwealth of Kentucky

*S/Jonathan E. Farmer*

Jonathan E. Farmer

Deputy Executive Director of Consumer Protection

Office of the Attorney General of Kentucky

1024 Capital Center Drive, Suite 200

Frankfort, KY 40601

Tel: 502-696-5448

Fax: 502-573-8317

Jonathan.Farmer@ky.gov

*Attorney for the Commonwealth of Kentucky*

Dated: 05/13/2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
KENTUCKY**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Kentucky (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 03/06/2026

Signature: Matt Kleinert

Name: Matthew Kleinert

Position/Title: Executive Director

Kentucky MFCU

**Single State Agency for Medicaid**

Dated: 03/06/26

Signature: *Lisa D. Lee*

Name: Lisa D. Lee

Position/Title: Commissioner

Kentucky Department for Medicaid Services

**FOR PLAINTIFF STATE OF MAINE  
AARON M. FREY  
ATTORNEY GENERAL**

/s/ Christina M. Moylan

Christina M. Moylan  
Assistant Attorney General  
Office of the Maine Attorney General  
6 State House Station  
Augusta, Maine 04333-0006  
Tel: (207) 626-8800  
christina.moylan@maine.gov

*Counsel for the Plaintiff State of Maine*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
MAINE**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Maine (the “State”) regarding the Settlement Agreement:


**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/2/2026

  
\_\_\_\_\_  
William R. Savage  
Assistant Attorney General, Director, Healthcare Crimes Unit  
MAINE OFFICE OF THE ATTORNEY GENERAL



**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE SINGLE  
STATE AGENCY FOR  
MAINE**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Maine (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: \_\_\_\_\_ Signature: \_\_\_\_\_  
Name: \_\_\_\_\_  
Position/Title: \_\_\_\_\_  
\_\_\_\_\_

**Single State Agency for Medicaid**

Dated: 3/2/2026 Signature: *Sara Gagné-Holmes*  
Name: Sara Gagné-Holmes  
Position/Title: Commissioner  
Maine Dept. of Health & Human Svcs.



FOR PLAINTIFF STATE OF MARYLAND:

ANTHONY G. BROWN  
ATTORNEY GENERAL

/s/Schonette J. Walker

Schonette J. Walker

Assistant Attorney General

Chief, Antitrust Division

200 Saint Paul Place

19<sup>th</sup> Floor

Baltimore, Maryland 21202

410.576.6473

[swalker@oag.maryland.gov](mailto:swalker@oag.maryland.gov)

Counsel for Plaintiff State

Maryland

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
MARYLAND**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Maryland (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**


By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/11/2026

Signature: \_\_\_\_\_



Name: W. Zak Shirley

Position/Title: Director

Maryland Medicaid Fraud and Vulnerable Victims Unit

**Single State Agency for Medicaid**

Dated:  
\_\_\_\_ **3/11/2026** \_\_\_\_

Signature:  \_\_\_\_\_

Name: \_\_\_\_\_  
Meena Seshamani, MD, PhD

Position/Title: \_\_\_\_\_  
Secretary of Health

\_\_\_\_\_

ANDREA JOY CAMPBELL,  
ATTORNEY GENERAL

/s/ Anthony Mariano

Anthony Mariano, MA No. 688559  
Chief, Antitrust Division  
Jennifer E. Greaney, MA No. 643337  
Deputy Chief, Antitrust Division  
Office of the Massachusetts Attorney General  
One Ashburton Place, 18th Floor  
Boston, Massachusetts 02108  
Tel: (617) 963-2981  
jennifer.greaney@mass.gov

*Counsel for the Commonwealth of Massachusetts*

Dated: June 9, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
MASSACHUSETTS**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the Commonwealth of Massachusetts (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/5/26

Signature: 

Name: Kevin Lownds

Position/Title: Division Chief

Medicaid Fraud Division

**Single State Agency for Medicaid**

Dated: 3/3/2016 Signature:   
Name: Dr. Kiame Mahaniah  
Position/Title: Secretary  
Executive Office of Health and Human Services

**FOR PLAINTIFF PEOPLE OF THE STATE OF MICHIGAN:**

DANA NESSEL

Attorney General of Michigan



---

SCOTT A. MERTENS

Section Head

Corporate Oversight Division

[MertensS@michigan.gov](mailto:MertensS@michigan.gov)




---

JONATHAN S. COMISH

Assistant Attorney General

Corporate Oversight Division

[ComishJ@michigan.gov](mailto:ComishJ@michigan.gov)



---

LEANN D. SCOTT

Assistant Attorney General

Corporate Oversight Division

[ScottL21@michigan.gov](mailto:ScottL21@michigan.gov)

Michigan Department of Attorney General

525 W Ottawa St.

Lansing, MI 48933

Telephone: 517-335-7622

Attorneys for Plaintiff People of the State of Michigan



**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
MICHIGAN**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Michigan (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 05/18/2026

Signature: 


Name: Timothy C. Erickson

Position/Title: First Assistant

Health Care Fraud Division – MI Attorney General

**Single State Agency for Medicaid**

Dated: 5/18/26

Signature: 

Name: Meghan E. Groen

Position/Title: Chief Deputy Director

Health Services

FOR PLAINTIFF STATE OF MINNESOTA

KEITH ELLISON  
ATTORNEY GENERAL

/s/ Jon M. Woodruff

Jon M. Woodruff

Assistant Attorney General

Office of the Minnesota Attorney General

445 Minnesota Street, Suite 600

Saint Paul, MN 55101

(651) 300-7425

jon.woodruff@ag.state.mn.us

*Counsel for the State of Minnesota*

Dated: June 5, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
MINNESOTA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Minnesota (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3-2-26

Signature: 

Name: Nicholas Wanka

Position/Title: Director, Minnesota MFCU

**Single State Agency for Medicaid**

Dated: 2/27/26 Signature: 

Name: James H. Clark III

Position/Title: Inspector General

Minnesota Department of Human Services

STATE OF MISSISSIPPI  
LYNN FITCH, ATTORNEY GENERAL

/s/ Tricia L. Beale

---

Tricia L. Beale, Esq. (MSB #99113)  
Special Assistant Attorney General  
Consumer Protection Division  
Mississippi Attorney General's Office  
2555 14<sup>th</sup> Street  
Gulfport, Mississippi 39501  
Telephone: 228-386-4404  
[tricia.beale@ago.ms.gov](mailto:tricia.beale@ago.ms.gov)

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
MISSISSIPPI**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of MISSISSIPPI (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 6/19/26

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Position/Title: \_\_\_\_\_

Martin A. Miller

MARTIN A. MILLER

Director MFCU

Mississippi Attorney General's Office

**Single State Agency for Medicaid**

Dated: 6/19/2026 Signature: Cindy Bradshaw  
Name: Cindy Bradshaw  
Position/Title: Executive Director  
Mississippi Division of Medicaid



STATE OF MONTANA  
AUSTIN KNUDSEN  
Attorney General

Anna Schneider  
Special Assistant Attorney General, Senior Counsel  
MONTANA DEPARTMENT OF JUSTICE  
OFFICE OF CONSUMER PROTECTION  
215 N. Sanders Street 59601  
(406) 444-4500  
[anna.schneider@mt.gov](mailto:anna.schneider@mt.gov)

*Counsel for the State of Montana*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
MONTANA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Montana (the "State") regarding the Settlement Agreement:


**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 2/20/2026

Signature: 

Name: Jacob Griffith

Position/Title: Director

Montana Medicaid Fraud Control Unit

BY: MICHAEL T. HILGERS  
Nebraska Attorney General

BY: /s/Justin C. McCully  
Justin C. McCully  
Assistant Attorney General  
Nebraska Attorney General's Office  
1445 K. St. Rm. 2115  
Lincoln, NE 68509-8920  
Telephone: (402) 471-2682  
Fax: (402) 471-4725  
[Justin.mccully@nebraska.gov](mailto:Justin.mccully@nebraska.gov)

*Counsel for Plaintiff State of Nebraska*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
NEBRASKA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of NEBRASKA (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.


**Medicaid Fraud Control Unit**

Dated: 2.17.2026

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Position/Title: \_\_\_\_\_

  
D. Mark Collins  
Assistant Attorney General  
Nebraska Dept. of Justice

**Single State Agency for Medicaid**

Dated: 2-24-2024

Signature: \_\_\_\_\_

A handwritten signature in blue ink, appearing to read "Drew Gonshorowski", written over a horizontal line.

Name: \_\_\_\_\_

Drew Gonshorowski

Position/Title: \_\_\_\_\_

Director, MLIC

PLAINTIFF STATE OF NEVADA:

AARON D. FORD

NEVADA ATTORNEY GENERAL

By: /s/ Lucas J. Tucker  
Lucas J Tucker  
Senior Deputy Attorney General  
Nevada Attorney General, Bureau of Consumer Protection  
8945 West Russell Road, Suite 204  
Las Vegas, Nevada 89148  
(702) 486-3256  
[ltucker@ag.nv.gov](mailto:ltucker@ag.nv.gov)

*Counsel for the State of Nevada*

Date: May 14, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
Nevada**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Nevada (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 5/15/24 Signature:   
Name: ANDREW SCHULKE  
Position/Title: CHIEF DEPUTY ATTORNEY GENERAL  
MFCU

**Single State Agency for Medicaid**

Dated: 05/15/26

Signature:



Name:

Position/Title: Stacie Weeks

Director



Glenmark

JOHN M. FORMELLA  
Attorney General

/s/Alexandra C. Sosnowski  
Alexandra C. Sosnowski  
Senior Assistant Attorney General  
New Hampshire Department of Justice  
Consumer Protection and Antitrust Bureau  
One Granite Place South  
Concord, N.H. 03301  
(603) 271-2678  
[Alexandra.C.Sosnowski@doj.nh.gov](mailto:Alexandra.C.Sosnowski@doj.nh.gov)

*Counsel for the State of New Hampshire*

Dated: 2/27/2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
NEW HAMPSHIRE**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of New Hampshire (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 2/13/26

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Position/Title: \_\_\_\_\_

Charles Bucca  
Director, NH MFCU

**Single State Agency for Medicaid**

Dated: 2/6/26 Signature: Henry D. Lipman  
Name: Henry D. Lipman  
Position/Title: Medicaid Director

**JENNIFER DAVENPORT**

Attorney General of New Jersey

By: /s/ Yale A. Leber

Yale A. Leber

Deputy Attorney General

New Jersey Attorney General's Office

25 Market Street, P.O. Box 106

Trenton, NJ 08625

Telephone: (862) 381-4159

E-Mail: [yale.leber@law.njoag.gov](mailto:yale.leber@law.njoag.gov)

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
NEW JERSEY**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of New Jersey (the “State”) regarding the Settlement Agreement:


**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 2/18/2026

Signature:   
Name: Al Garcia

Position/Title: Interim Insurance Fraud Prosecutor  
Office of the Attorney General

**Single State Agency for Medicaid**

Dated: 3/4/2026

Signature: Gregory Woods

Name: Gregory Woods

Position/Title: Assistant Commissioner  
Division of Medical Assistance and Health Services  
Department of Human Services

FOR PLAINTIFF STATE OF NEW MEXICO  
RAÚL TORREZ  
ATTORNEY GENERAL

/s/ Anthony R. Juzaitis

Anthony R. Juzaitis  
Assistant Attorney General  
408 Galisteo Street  
Santa Fe, New Mexico 87501  
Tel: 505-651-7565  
ajuzaitis@nm DOJ.gov

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
NEW MEXICO**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of New Mexico (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/4/24 Signature:   
Name: Jessica Randall  
Position/Title: Director  
New Mexico Medicaid Fraud Control Unit



**Single State Agency for Medicaid**

Dated: 3/4/26

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Rose Bryan

Position/Title: \_\_\_\_\_

Chief General Counsel

New Mexico Health Care Authority fka New Mexico  
Human Services Department

**New York's signature of the Glenmark settlement**

Respectfully submitted

LETITIA JAMES  
Attorney General of the State of New York

CHRISTOPHER D'ANGELO  
Chief Deputy Attorney General  
Economic Justice Division

ELINOR R. HOFFMANN  
Chief, Antitrust Bureau  
AMY MCFARLANE  
Deputy Bureau Chief, Antitrust Bureau

\_\_\_\_\_/s/ Robert L. Hubbard  
ROBERT L. HUBBARD  
SAAMI ZAIN  
ISABELLA PITT  
BENJAMIN COLE  
Assistant Attorneys General  
28 Liberty Street, 20<sup>th</sup> Floor  
New York, NY 10005  
212 416-8267  
[Robert.Hubbard@ag.ny.gov](mailto:Robert.Hubbard@ag.ny.gov)

ATTORNEYS FOR THE STATE OF NEW YORK

Pursuant to this settlement agreement ("Agreement"), the New York State Attorney General will recommend that the Office of the Medicaid Inspector General NOT exercise its authority to impose permissive exclusion on Bausch based on the covered Conduct, as defined in the Agreement.

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT FOR  
THE STATE OF NEW YORK**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) for the State of New York (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By its signature below, the Medicaid Fraud Control Unit has reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 7-6-26

Signature: 

Name: Amy Held

Position/Title: Director, Medicaid Fraud Control Unit

Office of the Attorney General of New York State

PLAINTIFF STATE OF NORTH CAROLINA  
JEFF JACKSON  
ATTORNEY GENERAL

/s/ Francisco Benzoni

Francisco Benzoni  
Special Deputy Attorney General  
Kimberly D'Arruda  
Special Deputy Attorney General  
Director of Technology, Healthcare, and Antitrust Section  
North Carolina Department of Justice  
Consumer Protection Division  
114 West Edenton Street  
Raleigh, NC 27603  
Telephone: (919) 716-6000  
fbenzoni@ncdoj.gov  
kdarruda@ncdoj.gov

*Counsel for Plaintiff State of North Carolina*

Dated: 05/13/2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
North Carolina**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of North Carolina (the “State”) regarding the Settlement Agreement:


**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**


Dated: 2/16/2026

Signature: 

Name: F. Edward Kirby Jr.

Position/Title: Director, NCDOJ, Medicaid Investigations Division


**Single State Agency for Medicaid**

Dated: 02/23/26 | 4:56 PM EST Signature:  \_\_\_\_\_  
Name: Jay Ludlam  
Position/Title: Deputy Secretary, NC Medicaid  
NCDHHS, Division of Health Benefits

STATE OF NORTH DAKOTA

Drew H. Wrigley

Attorney General



Elin S. Alm

Assistant Attorney General

Director, Consumer Protection & Antitrust Division

Office of Attorney General

1720 Burlington Drive, Suite C

Bismarck, ND 58504-7736

Tel: (701) 328-5570

[ealm@nd.gov](mailto:ealm@nd.gov)

*Counsel for North Dakota*

Dated: February 7, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
NORTH DAKOTA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of North Dakota (the "State") regarding the Settlement Agreement:

[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)


By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 15<sup>th</sup>  
April, 2026

Signature: \_\_\_\_\_



Name: Jessica J. Binder


Position/Title: Director – Medicaid Fraud Control Unit

Assistant Attorney General



Single State Agency for Medicaid

Dated:  
April 15, 2026

Signature: \_\_\_\_\_

Name: J. Patrick Traynor

Position/Title: Interim Commissioner

ND Department of Health & Human Services

COMMONWEALTH OF THE  
NORTHERN MARIANA ISLANDS

/s/ Stephen Anson

Stephen T. Anson

Assistant Attorney General

CNMI Office of the Attorney General

2<sup>nd</sup> Floor Hon. Juan A. Sablan Mem. Bldg.

Caller Box 10007

Capitol Hill

Saipan, MP 96950

Tele: (670) 237-7500

Fax: (670) 664-2349

[stephen\\_anson@cnmioag.org](mailto:stephen_anson@cnmioag.org)

*Counsel for the Commonwealth of the Northern Mariana Islands*

FOR PLAINTIFF STATE OF OHIO:

DAVE YOST  
ATTORNEY GENERAL

/s/ Edward J. Olszewski  
Edward J. Olszewski, Assistant Section Chief, Antitrust  
Office of Ohio Attorney General  
30 East Broad Street, 26<sup>th</sup> Floor  
Columbus, Ohio 43215  
Phone: 614.466.4328  
Edward.Olszewski@OhioAGO.gov

*Counsel for Plaintiff State of Ohio*

Dated: March 19, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR**

**[STATE]  
OHIO**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of [STATE] (the "State") regarding the Settlement Agreement:

**OHIO**

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/4/26

Signature: \_\_\_\_\_



Name: \_\_\_\_\_

Ben Karrasch

Position/Title: \_\_\_\_\_

Director. Ohio MFCU

Secction Chief HCF Ohio AGO

**Single State Agency for Medicaid**

Dated: 3/4/2026

Signature: \_\_\_\_\_



Name: \_\_\_\_\_

Scott Partika

Position/Title: \_\_\_\_\_

Director

s/ Christopher J. Campbell

Christopher J. Campbell (admitted *pro hac vice*)

Assistant Attorney General

Office of the Oklahoma Attorney General

313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone: (405) 522-0858

Email: Chris.Campbell@oag.ok.gov

*Counsel for Plaintiff State of Oklahoma*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
STATE OF OKLAHOMA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Oklahoma (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: March 6, 2026

Signature: 

Name: Jeb Joseph


Position/Title: Deputy Director

Oklahoma Medicaid Fraud Control Unit

**Single State Agency for Medicaid**

Dated: 3/5/2026

Signature:

A handwritten signature in black ink, appearing to read "Melissa Miller", written over a horizontal line.

Name:

Melissa Miller

Position/Title:

State Medicaid Director/Deputy Chief of Staff



**FOR PLAINTIFF STATE OF OREGON**

DAN RAYFIELD  
ATTORNEY GENERAL FOR THE  
STATE OF OREGON

s/ Gina Ko

Gina Ko

Assistant Attorney General  
Economic Justice Section  
Oregon Department of Justice  
100 SW Market Street  
Portland, OR 97201  
Tel: (971) 673-1880  
Fax: (503) 378-5017  
gina.ko@doj.oregon.gov

*Counsel for Plaintiff State of Oregon*

Dated 05/14/2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
OREGON**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Oregon (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: **3/17/2026**

Signature: 

Name: Sheen Y. Wu

Position/Title: Director / AIC

Oregon DOJ MFCU

**Single State Agency for Medicaid**

Dated: 3.09.2026

Signature:



Name: Fritz Jenkins

Position/Title: Administrator for Program Integrity

Oregon Health Authority

/s/ Tracy W. Wertz

Tracy W. Wertz

Chief Deputy Attorney General

Antitrust Section

Joseph S. Betsko

Assistant Chief Deputy Attorney General

Jessica Kuehn

Senior Deputy Attorney General

Pennsylvania Office of Attorney General

Strawberry Square, 14th Floor

Harrisburg, PA 17120

Phone: (717) 787-4530

Fax: (717) 787-1190

[twertz@attorneygeneral.gov](mailto:twertz@attorneygeneral.gov)

*Counsel for the Commonwealth of Pennsylvania*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
PENNSYLVANIA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Pennsylvania (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/5/26

Signature: \_\_\_\_\_



Name: \_\_\_\_\_

Heather M. Albright

Position/Title: \_\_\_\_\_

Chief Deputy Attorney General

**Single State Agency for Medicaid**

Dated: 3/5/2016

Signature: 

Name: Karen L. Fickes

Position/Title: Director

Department of Human Services  
Bureau of Program Integrity

**GLENMARK STATE AG SETTLEMENT AGREEMENT**

FOR PLAINTIFF COMMONWEALTH OF PUERTO RICO:

LOURDES L. GÓMEZ-TORRES  
ATTORNEY GENERAL

/s/ Tania Fernández-Medero  
TANIA L. FERNÁNDEZ-MEDERO  
DEPUTY ATTORNEY GENERAL  
ANTITRUST DIVISION  
Puerto Rico Department of Justice  
P.O. Box 9020192  
San Juan, P.R. 00902-0192  
Phone: (787) 721-2900, Ext. 1204  
Email: tfernandez@justicia.pr.gov

*Counsel for the Commonwealth of Puerto Rico*

Dated: May 22, 2026



**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
PUERTO RICO**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of PUERTO RICO (the "State") regarding the Settlement Agreement:

[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 03/06/26 Signature:   
Name: Luis Freire  
Position/Title: DIRECTOR  
PR MFCU



Single State Agency for Medicaid

Dated: 3/6/2025 Signature:   
Name: Maria R. Maria Lucio  
Position/Title: Program Integrity Director  
PR Medicaid Program

**FOR PLAINTIFF STATE OF  
RHODE ISLAND  
PETER F. NERONHA  
ATTORNEY GENERAL**

/s/ Alex Carnevale

Alex Carnevale

Special Assistant Attorney General

Office of the Attorney General

State of Rhode Island

150 South Main Street

Providence, RI 02903

Tel: (860) 287 7156

[acarnevale@riag.ri.gov](mailto:acarnevale@riag.ri.gov)

*Counsel for the Plaintiff  
State of Rhode Island*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
Rhode Island**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Rhode Island (the "State") regarding the Settlement Agreement:

[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: \_\_\_\_\_

3/9/2026

Signature: \_\_\_\_\_



Name: \_\_\_\_\_

Andrea M. Mauro

Position/Title: \_\_\_\_\_

Director - RIAG Medicaid Fraud Control Unit  
Office of the Rhode Island Attorney General

**Single State Agency for Medicaid**

Dated: 3/6/26

Signature: **Jane E Morgan** Digitally signed by Jane E Morgan  
Date: 2026.03.06 21:00:26 -05'00'

Name: Jane E. Morgan, Esq.

Position/Title: Medicaid Program Deputy Director

Legal Compliance and Program Integrity

**FOR PLAINTIFF THE STATE OF SOUTH CAROLINA**

Alan Wilson  
Attorney General of South Carolina

/s/Mary Frances G. Jowers

Mary Frances G. Jowers  
Assistant Deputy Attorney General  
South Carolina Office of the Attorney General  
PO Box 11549  
Columbia, SC 29211  
803-734-3996  
mfjowers@scag.gov

*Counsel for the State of South Carolina*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
SOUTH CAROLINA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of SOUTH CAROLINA (the "State") regarding the Settlement Agreement:


**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 2/24/2026

Signature: 

Name: Stephanie G. Opet


Position/Title: Director, Medicaid Fraud Control Unit

South Carolina Office of the Attorney General

**Single State Agency for Medicaid**

Dated: 2/24/26

Signature:

A handwritten signature in black ink, appearing to read 'Sarah Hearn-Bailey', written over a horizontal line.

Name:

Sarah Hearn-Bailey

Position/Title:

Assistant General Counsel

South Carolina Department of Health and Human  
Services

PLAINTIFF STATE OF SOUTH DAKOTA  
MARTY J. JACKLEY  
ATTORNEY GENERAL

/s/ Amanda Miiller

Amanda Miiller

Deputy Attorney General

South Dakota Office of the Attorney General

1302 East SD Highway 1889, Suite 1

Pierre, SD 57501-8501

Telephone: (605) 773-3215

Email: [amanda.miiller@state.sd.us](mailto:amanda.miiller@state.sd.us)

*Counsel for Plaintiff State of South Dakota*

Dated: February 27, 2026



**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
SOUTH DAKOTA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of South Dakota (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 02-27-26

Signature: \_\_\_\_\_

Stephen Gemar

Name: \_\_\_\_\_

Stephen Gemar

Position/Title: \_\_\_\_\_

MFCU Director

South Dakota Office of the Attorney General

**Single State Agency for Medicaid**

Dated:

02/27/2026

Signature:

Name:



Position/Title:

Heather Petermann

Medicaid Director

Dept. of Social Services, Division of Medical  
Services

**State of Tennessee**  
**Jonathan Skrmetti**  
**Attorney General**

*Austin C. Ostiguy*

Austin C. Ostiguy  
Assistant Attorney General  
Daniel Lynch  
Assistant Attorney General  
P.O. Box 20207  
Nashville, TN 37202  
Tel: (615) 532-7271  
Austin.Ostiguy@ag.tn.gov  
Counsel for Tennessee  
Dated: 5/22/2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
TENNESSEE**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of TENNESSEE (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 2-20-2026 Signature:   
Name: Gene Stegall  
Position/Title: Director, Tennessee Medicaid Fraud Control Unit

**Single State Agency for Medicaid**

Dated: 3.5.26

Signature:



Name:

Stephen Smith

Position/Title:

Director

Executed April 1, 2026

Respectfully submitted,

FOR PLAINTIFF STATE OF UTAH  
DEREK E. BROWN  
UTAH ATTORNEY GENERAL



Marie W.L. Martin  
Division Director,  
Antitrust & Data Privacy Division  
Office of the Attorney General of Utah  
including as counsel for the Utah Division of Consumer Protection  
160 East 300 South, 5<sup>th</sup> Floor  
P.O. Box 140830  
Salt Lake City, UT 84114-0830  
Tel: 801-366-0375  
Fax: 801-366-0378  
[mwmartin@agutah.gov](mailto:mwmartin@agutah.gov)

*Attorneys for the State of Utah*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
UTAH**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Utah (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: Feb 19, 2026

Signature:   
Kaye Lynn Wootton (Feb 19, 2026 20:01:02 MST)

Name: Kaye Lynn Wootton

Position/Title: Director

Medicaid Fraud Control Unit, Utah AG



**Single State Agency for Medicaid**

Dated: Feb 25, 2026

Signature: 

Name: Julie Ewing

Position/Title: Utah State Medicaid Director

Utah Department of Health and Human Services



/s/ Jill S. Abrams

Jill S. Abrams

Assistant Attorney General

Vermont Attorney General

109 State Street

Montpelier, VT 05609

(802) 828-1106

[Jill.abrams@vermont.gov](mailto:Jill.abrams@vermont.gov)

*Counsel for the State of Vermont*

Dated: February 26, 2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
VERMONT**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Vermont (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

|                             |                                                                            |
|-----------------------------|----------------------------------------------------------------------------|
| Dated: <u>March 5, 2026</u> | Signature: <u><i>Elizabeth L. Anderson</i></u>                             |
|                             | Name: <u>Elizabeth L .Anderson</u>                                         |
|                             | Position/Title: <u>Director, Medicaid Fraud and Residential Abuse Unit</u> |
|                             | <u>Office of the Vermont Attorney General</u>                              |

**Single State Agency for Medicaid**

Dated: **3/5/2026**\_\_\_\_\_

Signature: DaShawn Groves

Digitally signed by  
DaShawn Groves  
Date: 2026.03.05 14:23:41  
-05'00'

\_\_\_\_\_

Name: DaShawn Groves

\_\_\_\_\_

Position/Title: Commissioner

\_\_\_\_\_

\_\_\_\_\_

**FOR PLAINTIFF COMMONWEALTH OF VIRGINIA  
JAY JONES  
ATTORNEY GENERAL**

/s/ Tyler T. Henry

Tyler T. Henry  
Senior Assistant Attorney General  
Office of the Attorney General of Virginia  
202 North 9th Street  
Richmond, Virginia 23219  
Tel: (804) 692-0485  
THenry@oag.state.va.us

*Counsel for Plaintiff Commonwealth of Virginia*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR THE COMMONWEALTH OF VIRGINIA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the Commonwealth of Virginia (the "State") regarding the Settlement Agreement:

[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/4/2026

Signature: 

Name: Jill S. Costen


Position/Title: Director and Chief

Medicaid Fraud Control Unit

**Single State Agency for Medicaid**

Dated: 2/24/2026

Signature:

A handwritten signature in dark ink, appearing to read "Jeffrey Lunardi", written over a horizontal line.

Name: Jeffrey Lunardi

Position/Title: Interim Director

Department of Medical Assistance Services

**GORDON C. RHEA, ESQ**  
**ATTORNEY GENERAL**

BY: Christopher M. Timmons, Esq.

**CHRISTOPHER M. TIMMONS, ESQ.**

Chief, Civil Division

Virgin Islands Department of Justice

6151 Estate La Reine

Kingshill, VI, 00851

[christopher.timmons@doj.vi.gov](mailto:christopher.timmons@doj.vi.gov)

(340) 773-0295

**Single State Agency for Medicaid**

Dated: 5/21/2026

Signature: Gary D. Smith

Name: Gary Smith

Position/Title: Medicaid Director



**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
[USVI]**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of [USVI] (the "State") regarding the Settlement Agreement:

[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.


This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated:

5/21/2026

Signature:



Name:

Lilita de Leon

Position/Title:

Director MFCU

**FOR PLAINTIFF STATE OF WASHINGTON**

NICHOLAS W. BROWN  
ATTORNEY GENERAL

s/ Paula Pera C.

Paula Pera C.

Holly A. Williams

Assistant Attorneys General, Antitrust Division

Washington State Office of the Attorney General

800 Fifth Avenue, Suite 2000

Seattle, WA 98104-3188

Tel: (206) 464-7744

paula.pera@atg.wa.gov

holly.williams@atg.wa.gov

*Attorneys for Plaintiff State of Washington*

Dated 03/19/2026

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
WASHINGTON**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Washington (the “State”) regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, (“Glenmark”) and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement’s approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/24/26

Signature: Larissa Payne

Name: Larissa Payne

Position/Title: Director

Washington Medicaid Fraud & Abuse Division

**Single State Agency for Medicaid**

Dated: 03/24/2026

Signature: 

Name: Trinity Wilson

Position/Title: Interim Medicaid Director

Health Care Authority

**FOR PLAINTIFF STATE OF WEST VIRGINIA  
JOHN B. MCCUSKEY  
ATTORNEY GENERAL**

/s/ Douglas L. Davis

Douglas L. Davis

Senior Assistant Attorney General

West Virginia Attorney General's Office

Consumer Protection and Antitrust Division

P.O. Box 1789

Charleston, WV 25326

Telephone: (304) 558-8986

douglas.l.davis@wvago.gov

*Counsel for the Plaintiff State of West Virginia*



**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
WEST VIRGINIA**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of West Virginia (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 3/4/2026 Signature:   
Name: Lauren E. Plymale  
Position/Title: Director, WV Medicaid Fraud Control Unit, WV Attorney General

**Single State Agency for Medicaid**

Dated: 3/4/26 Signature: Christy Donohue  
Name: Christy Donohue  
Position/Title: Commissioner  
WV DoHS / BMS

**FOR PLAINTIFF STATE OF WISCONSIN**  
**JOSHUA L. KAUL**  
**ATTORNEY GENERAL**

/s/Caitlin M. Madden

Caitlin M. Madden  
Assistant Attorney General  
Wisconsin Department of Justice  
17 West Main Street  
Post Office Box 7857  
Madison, WI 53707-7857  
(608) 267-1311  
[caitlin.madden@wisdoj.gov](mailto:caitlin.madden@wisdoj.gov)

*Counsel for the State of Wisconsin*

Dated: April 27, 2026





**Single State Agency for Medicaid**

Dated: 2-27-2026 Signature: 

Name: Anthony J. Baize

Position/Title: Inspector General

Wisconsin Dept. of Health Services

PLAINTIFF STATE OF WYOMING  
KEITH G. KAUTZ  
ATTORNEY GENERAL

/s/ Cameron W. Geeting

Cameron W. Geeting  
Senior Assistant Attorney General  
Consumer Protection & Antitrust Unit (CPAU)  
Wyoming Attorney General's Office  
2320 Capitol Avenue  
Cheyenne, WY 82002  
(307) 777-3795  
cameron.geeting1@wyo.gov

*Counsel for Plaintiff State of Wyoming*

**SIGNATURE PAGE FOR THE MEDICAID FRAUD CONTROL UNIT AND THE  
SINGLE STATE AGENCY FOR  
WYOMING**

As conditioned herein, this Signature Page shall serve as the Statement of Review and Approval of the Medicaid Fraud Control Unit (MFCU) and the Single State Agency for Medicaid (SSA) for the State of Wyoming (the "State") regarding the Settlement Agreement:

**[B]y and among Glenmark Pharmaceuticals, Inc., USA, ("Glenmark") and the States, by and through their respective Attorneys General [with respect to] claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 ("MDL"), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.)**

By their respective signatures below, the Medicaid Fraud Control Unit and the Single State Agency for Medicaid for the State have reviewed the Agreement and, with respect to the release of Medicaid claims (as particularly specified in, and as limited by, the Agreement), approves the Agreement.

This approval, as limited herein, is conditional upon Execution of the Agreement by the State and the other Parties to the Agreement, and upon the Agreement's approval by a court of proper jurisdiction.

**Medicaid Fraud Control Unit**

Dated: 2/17/2026

Signature: 

Name: Travis J. Kirchhefer

Position/Title: Director & Sr. Assistant Attorney General

Medicaid Fraud Control Unit  
Office of the Wyoming Attorney General

**Single State Agency for Medicaid**

Dated: 2-23-2026 Signature: 

Name: Andrew Chapin

Position/Title: Program Integrity Section Manager

Division of Healthcare Financing,  
Wyoming Department of Health

**Appendix A**

**State Drugs at Issue**

Acetazolamide  
Adapalene  
Alclometasone Dipropionate  
Amiloride HCL/HCTZ  
Ammonium Lactate  
Amoxicillin/Clavulanate  
Amphetamine/Dextroamphetamine  
Azithromycin  
Baclofen  
Benazepril HCTZ  
Betamethasone Dipropionate  
Betamethasone Dipropionate Augmented  
Betamethasone Valerate  
Bethanechol Chloride  
Bromocriptine Mesylate  
Budesonide  
Bumetanide  
Buspirone Hydrochloride  
Cabergoline  
Calcipotriene Betamethasone Dipropionate Ointment  
Calcipotriene Solution  
Capecitabine  
Carbamazepine  
Cefdinir  
Cefpodoxime Proxetil Oral Suspension  
Cefpodoxime Proxetil Tablets  
Cefprozil  
Celecoxib  
Cephalexin (Cefalexin)  
Chlorpromazine HCL  
Cholestyramine  
Ciclopirox  
Cimetidine  
Ciprofloxacin HCL Tablet  
Clarithromycin  
Clemastine Fumarate  
Clindamycin Phosphate  
Clobetasol  
Clomipramine HCL

Clonidine TTS  
Clotrimazole  
Cyproheptadine HCL  
Desmopressin Acetate  
Desogestrel and Ethinyl Estradiol [Kariva]  
Desonide  
Desoximetasone  
Dexmethylphenidate HCL [Focalin]  
Dextroamphetamine Sulfate (“Dex Sulfate”)  
Diclofenac Potassium  
Dicloxacillin Sodium  
Diflunisal  
Diltiazem HCL  
Disopyramide Phosphate  
Doxazosin Mesylate  
Doxycycline Hyclate  
Doxycycline Monohydrate  
Drospirenone and Ethinyl Estradiol  
Econazole  
Enalapril Maleate  
Entecavir  
Epitol  
Eplerenone  
Erythromycin  
Estazolam  
Estradiol  
Estradiol and Norethindrone Acetate [Mimvey]  
Ethambutol HCL  
Ethinyl Estradiol and Levonorgestrel [Portia and Jolessa]  
Ethosuximide  
Etodolac  
Fenofibrate  
Fluconazole  
Fluocinolone Acetonide  
Fluocinonide  
Fluoxetine HCL  
Flurbiprofen  
Flutamide  
Fluticasone Propionate  
Fluvastatin Sodium  
Fosinopril HCTZ  
Gabapentin  
Glimepiride  
Glipizide-Metformin

Glyburide  
Glyburide-Metformin  
Griseofulvin  
Halobetasol Propionate  
Haloperidol  
Hydrocortisone Valerate  
Hydroxyurea  
Hydroxyzine Pamoate  
Imiquimod  
Irbesartan  
Isoniazid  
Ketoconazole  
Ketoprofen  
Ketorolac Tromethamine  
Labetalol HCL  
Lamivudine/Zidovudine  
Latanoprost  
Leflunomide  
Levothyroxine  
Lidocaine Ointment  
Loperamide HCL  
Medroxyprogesterone  
Meprobamate  
Methazolamide  
Methotrexate Sodium  
Methylphenidate  
Metronidazole  
Moexipril HCL  
Moexipril HCL HCTZ  
Mometasone  
Nabumetone  
Nadolol  
Nafcillin  
Niacin  
Nimodipine  
Nitrofurantoin (Macrocrystalline)  
Norethindrone Acetate  
Norethindrone and Ethinyl Estradiol [Balziva]  
Nortriptyline Hydrochloride  
Nystatin  
Nystatin/Triamcinolone  
Omega-3-Acid Ethyl Esters  
Oxacillin  
Oxaprozin



Oxybutynin Chloride  
Paricalcitol  
Paromomycin  
Penicillin VK  
Pentoxifylline  
Phenytoin Sodium  
Pioglitazone-Metformin  
Piroxicam  
Pravastatin  
Prazosin HCL  
Prochlorperazine  
Propranolol  
Raloxifene HCL  
Ranitidine HCL  
Tacrolimus  
Tamoxifen Citrate  
Temozolomide  
Terconazole  
Theophylline  
Tizanidine HCL  
Tobramycin Sulfate  
Tolmetin Sodium  
Tolterodine Tartate  
Topiramate  
Triamcinolone Acetonide  
Trifluoperazine HCL  
Valsartan HCTZ  
Verapamil  
Warfarin Sodium  
Zoledronic Acid

## Appendix B

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Alaska      | <ul style="list-style-type: none"><li>• Attorney General for the State of Alaska</li><li>• Alaska Department of Health (Medicaid)</li><li>• Alaska Department of Corrections</li><li>• All other executive branch state agencies that purchased drugs</li></ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Arizona     | <ul style="list-style-type: none"><li>• Attorney General for the State of Arizona</li><li>• Arizona Health Care Cost Containment System (AHCCCS) (Medicaid)</li></ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| California  | <ul style="list-style-type: none"><li>• Attorney General for the State of California</li><li>• California Department of Health Care Services (DHCS – Medicaid)</li><li>• California Public Employees Retirement System (CalPERS) to the extent that its clients are state agencies (local entities that are clients of CalPERS are excluded).</li><li>• California State University (CSU)</li><li>• California Department of State Hospitals (DSH) California Department of Corrections and Rehabilitation (CDCR)</li><li>• University of California (UC)</li><li>• California Department of General Services</li><li>• All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs</li></ul> |
| Colorado    | <ul style="list-style-type: none"><li>• Attorney General for the State of Colorado</li><li>• Colorado Department of Health Care Policy and Financing (Medicaid)</li><li>• All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs</li></ul>                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Connecticut | <ul style="list-style-type: none"><li>• Attorney General for the State of Connecticut</li><li>• Department of Social Services (as administrator of Medicaid)</li><li>• Department of Mental Health and</li></ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | <ul style="list-style-type: none"> <li>Addiction Services</li> <li>• Department of Developmental Services</li> <li>• Department of Public Health</li> <li>• Department of Veterans Affairs</li> <li>• Department of Corrections</li> <li>• All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs</li> </ul>                                                                                         |
| Delaware             | <ul style="list-style-type: none"> <li>• Attorney General for the State of Delaware</li> <li>• Delaware Division of Medicaid and Medical Assistance (Medicaid)</li> </ul>                                                                                                                                                                                                                                                                           |
| District of Columbia | <ul style="list-style-type: none"> <li>• Attorney General for the District of Columbia</li> <li>• Department of Health Care Finance (Medicaid)</li> </ul>                                                                                                                                                                                                                                                                                           |
| Florida              | <ul style="list-style-type: none"> <li>• Attorney General for the State of Florida</li> <li>• Florida Agency for Health Care Administration (Medicaid)</li> <li>• Department of Management Services</li> <li>• Department of Children and Families</li> <li>• Department of Corrections</li> <li>• Department of Health</li> <li>• All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs</li> </ul> |
| Georgia              | <ul style="list-style-type: none"> <li>• Attorney General for the State of Georgia</li> <li>• Georgia Department of Community Health (Medicaid)</li> </ul>                                                                                                                                                                                                                                                                                          |
| Idaho                | <ul style="list-style-type: none"> <li>• Attorney General for the State of Idaho</li> <li>• Idaho Department of Health and Welfare, Division of Medicaid (Medicaid)</li> <li>• Idaho State Entities with MMCAP purchases, as listed in the MMCAP data production when filtered for Idaho.</li> </ul>                                                                                                                                                |
| Illinois             | <ul style="list-style-type: none"> <li>• Attorney General for the State of Illinois</li> <li>• Illinois Department of Healthcare and Family Services (Medicaid)</li> </ul>                                                                                                                                                                                                                                                                          |

- Department of Central Management Services Department of Veterans Affairs (DVA)
  - All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs (where public universities and health systems are not State Entities)
- Indiana
- Attorney General for the State of Indiana
  - Indiana Family and Social Services Administration (Medicaid)
  - Department of Health
  - Department of Administration
  - Personnel Department
  - State Police
  - Veterans' Home
  - All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs
- Iowa
- Iowa Office of the Attorney General
  - Iowa Department of Health and Human Services (Medicaid)
- Kansas
- Attorney General for the State of Kansas
  - Kansas Department of Health and Environment (Medicaid)
  - Kansas Division of Health Care Finance
  - Kansas State Employee Health Plan (Kansas Department of Administration),
  - Kansas State Entities with MMCAP purchases:
    - (1) Adair Acute Care Pharmacy, Osawatomie State Hospital
    - (2) Emporia State University-Student Health
    - (3) Fort Hays State University-Student Health
    - (4) Kansas Neurological Institute
    - (5) Kansas Soldiers Home
    - (6) Kansas State School for the Blind

- (7) Kansas State School for the Deaf
- (8) Kansas State University- VMTH
- (9) Kansas State University- Lafen
- (10) Kansas Department of Health & Environment 340B STD
- (11) Kansas Department of Health & Environment 340B TB
- (12) Larned Stated Hospital
- (13) Osawatomic State Hospital
- (14) Parsons State Hospital & Training Center
- (15) Pharmacy Practice Integrated Lab, University of Kansas
- (16) Pittsburgh State University 340B
- (17) Pittsburgh State University, Student Health
- (18) Rainbow Mental Health Facility
- (19) Watkins Health Center Pharmacy, University of Kansas
- (20) Wichita Pharmacy Skills Lab, University of Kansas
- (21) Wichita State University Student Health)

Kentucky

- Kentucky Office of the Attorney General
- Kentucky Cabinet for Health and Family Services (Medicaid)

Maine

- Attorney General for the State of Maine
- Maine Department of Health and Human Services Office of MaineCare Services (Medicaid)
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

|               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Maryland      | <ul style="list-style-type: none"><li>• Maryland Office of the Attorney General</li><li>• Maryland Department of Human Services (Medicaid)</li></ul>                                                                                                                                                                                                                                                                                                                                                                                          |
| Massachusetts | <ul style="list-style-type: none"><li>• Attorney General for the State of Massachusetts</li><li>• MassHealth (Medicaid)</li><li>• State Office of Pharmacy Services (SOPS)</li><li>• Group Insurance Commission (GIC)</li></ul>                                                                                                                                                                                                                                                                                                               |
| Michigan      | <p>Attorney General for the State of Michigan</p> <ul style="list-style-type: none"><li>• Michigan Health &amp; Human Services (Medicaid)</li><li>• Michigan Department of Attorney General</li><li>• Michigan Department of Health and Human Services</li><li>• Michigan Department of Corrections</li><li>• Michigan Civil Service Commission</li><li>• Michigan Department of Technology, Management, and Budget</li><li>• All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs</li></ul> |
| Minnesota     | <ul style="list-style-type: none"><li>• Office of the Minnesota Attorney General</li><li>• Minnesota Department of Human Services</li><li>• Minnesota Department of Corrections</li><li>• Minnesota Department of Veterans Affairs</li><li>• Minnesota Management and Budget</li></ul>                                                                                                                                                                                                                                                        |
| Mississippi   | <ul style="list-style-type: none"><li>• Attorney General for the State of Mississippi</li><li>• Mississippi Division of Medicaid (Medicaid)</li><li>• Mississippi Department of Insurance</li><li>• Mississippi Department of Health</li><li>• All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs during the relevant time period (or from May 1, 2009 to the</li></ul>                                                                                                                    |

Effective Date)

Montana

- Montana Office of the Attorney General
- Montana Department of Public Health and Human Services (Medicaid)

Nebraska

- Nebraska Office of the Attorney General
- Department of Health and Human Services (Medicaid)
- Department of Administrative Services
- Department of Corrections
- Department of Veterans' Affairs
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

Nevada

- Attorney General for the State of Nevada
- Nevada Department of Health & Human Services Division of Health Care Financing and Policy (Medicaid)
- Nevada Public Employees' Benefits Program University of Nevada School of Medicine Department of Health and Human Services (HHS)- Division of Public and Behavioral Health
- Department of Health and Human Services (HHS)- Division of Child and Family Services
- Department of Health and Human Services- Division of Aging & Disability Services
- Nevada Department of Corrections; and
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

New Hampshire

- Attorney General for the State of New Hampshire
- New Hampshire Department of Health &

## Human Services (Medicaid)

## New Jersey

- Attorney General for the State of New Jersey
- State of New Jersey, Department of Human Services, Division of Medical Assistance & Health Services (Medicaid)

## New Mexico

- New Mexico Department of Justice
- New Mexico Human Services Department (Medicaid)
- New Mexico Department of Health
- New Mexico State Entities that made MMCAP purchases

New York<sup>1</sup>

- Attorney General for the State of New York
- State Department of Health (Medicaid)
- MMCAP State Entities, listed in the MMCAP production when you filter for New York. State Entities purchasing through MMCAP include hospitals operated by the State Office of Mental Health

## North Carolina

- Attorney General for the State of North Carolina
- North Carolina Medicaid, Division of Health Benefits (Medicaid)

## North Dakota

- Attorney General for the State of North Dakota
- North Dakota Health & Human Services, Medical Services Division (Medicaid)

## Northern Mariana Islands

- Office of the Attorney General for the Commonwealth of the Northern Mariana Islands
- Commonwealth Medicaid Center (Medicaid)
- All other State Entities that purchased, or

---

<sup>1</sup> The definition of Released Claims in Paragraph I.R is specifically modified to reflect that the State of New York does not release or waive its permissive exclusion or debarment authority as to the Bausch Releasees.



provided reimbursement for the purchase of, generic drugs

Ohio

- Attorney General for the State of Ohio
- Ohio Department of Medicaid (Medicaid)

Oklahoma

- Office of the Oklahoma Attorney General
- Oklahoma Healthcare Authority (Medicaid)
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

Oregon

- Attorney General for the State of Oregon
- Oregon Health Authority
- Health Authority Medicaid Program (Medicaid) Health Authority CAREAssist Program
- Health Authority- Oregon Educators Benefit Board & Oregon Public Employees Benefit Board
- Department of Corrections
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

Pennsylvania

- Attorney General for the State of Pennsylvania
- Pennsylvania Department of Human Services (Medicaid)
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

Puerto Rico

- Attorney General for Puerto Rico
- Administración de Seguros de Salud de Puerto Rico
- Departamento de Correccion y Rehabilitacion
- Puerto Rico Department of Health (Medicaid)
- All other State Entities that purchased, or provided reimbursement for the purchase

of, generic drugs other than (1) public corporations, and (2) public instrumentalities<sup>2</sup>

#### Rhode Island

- Rhode Island Office of the Attorney General
- Department of Human Services Medicaid Program

#### South Carolina

- Attorney General for the State of South Carolina
- South Carolina Healthy Connections (Medicaid)

---

<sup>2</sup> “Public corporation” and “public instrumentality” are defined as follows: Any public instrumentality that offers financial and/or social services to the People of Puerto Rico on behalf of the Government of the Commonwealth of Puerto Rico, but as an independent juridical entity. The definition shall include all the public-private corporation, to wit, any corporation that issues stocks and is organized pursuant to private corporations laws, but is controlled, in whole or in part, by the Government of the Commonwealth of Puerto Rico. The term shall refer, but is not limited to the Electric Power Authority; the Aqueduct and Sewer Authority; the University of Puerto Rico; the Automobile Accident Compensation Administration; the State Insurance Fund Corporation; the Labor Relations Board; the Public Building Authority; the Port Authority; the Government Development Bank; the Industrial Development Company; the Metropolitan Bus Authority; the Health Insurance Administration; the Trade and Export Company; the Motion Picture, Arts, Sciences, and Industry Development Corporation; the Highway and Transportation Authority; the Farm Insurance Corporation; the Rural Development Corporation; the Land Authority; the Land Administration; the Maritime Transport Authority; the Convention Center District Authority; the Solid Waste Authority; the Caribbean Basin Project Financing Authority; the Municipal Finance Agency; the Industrial, Tourist, Educational, Medical, and Environmental Pollution-Control Facilities Financing Authority; the Puerto Rico Infrastructure Financing Authority; the Housing Finance Authority; the Public Finance Corporation; the Economic Development Bank for Puerto Rico; the Corporation for the Revitalization of Urban Centers and Areas; the Right to Work Administration; the National Parks Company; the Corporation of Industries for the Blind, the Mentally Retarded and Other Disabled Persons of Puerto Rico; the Puerto Rico and Caribbean Cardiovascular Center Corporation; the Puerto Rico Medical Services Administration; the National Guard Institutional Trust; the Employment and Training Enterprises Corporation; the Corporation for the Supervision and Insurance of Cooperatives; the Port of the Americas Authority; the Company for the Integral Development of the Cantera Peninsula; the Puerto Rico Conservatory of Music Corporation; the Musical Arts Corporation; the Institute of Puerto Rican Culture; the Martin Peña Canal ENLACE Project Corporation; the Authority for the Redevelopment of Land and Facilities of the Roosevelt Roads Naval Station; the Traffic Safety Commission; the Administration for Integral Child Care and Development; Administration; and any other Public Corporations and Instrumentalities that are created and comply with the definition herein.”

Tennessee

- Attorney General for the State of Tennessee
- Tennessee Department of Finance & Administration, Division of TennCare (Medicaid)
- Tennessee Department of Finance & Administration, Division of Benefits Administration
- All State Entities that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price for any Drugs at Issue, other than for resale, from May 1, 2009 to the Effective Date.

Utah

- Attorney General for the State of Utah
- Utah Department of Health & Human Services (Medicaid)
- Division of Consumer Protection
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

Vermont

- Attorney General for the State of Vermont
- Agency of Human Services, Department of Vermont Health Access (Medicaid)
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

Virginia

- Attorney General for the State of Virginia
- Virginia Department of Medicaid Assistance Services (Medicaid)

Virgin Islands

- Attorney General for the U.S. Virgin Islands

- Virgin Islands Department of Human Services—Office of Medicaid (Medicaid)
- All other State Entities that purchased the drugs at issue, or that provided reimbursement for the purchase of the drugs at issue, during the period that is the subject of this action

Washington

- Attorney General for the State of Washington
- Washington State Department of Social and Health Services
- Washington State Health Care Authority (Medicaid)
- Department of Corrections
- Department of Labor and Industries (L&I)
- Eastern State Hospital, Department of Social and Health Services (DSHS)
- Western State Hospital, Department of Social and Health Services (DSHS)
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

West Virginia

- Attorney General for the State of West Virginia
- WV Dept. of Health and Human Services, Bureau for Medical Services (Medicaid)
- WV Public Employees Insurance Agency

Wisconsin

- Attorney General for the State of Wisconsin
- Wisconsin Department of Health Services (Medicaid)
- All other State Entities that purchased, or provided reimbursement for the purchase of, generic drugs

**Appendix C**

**GLENMARK COOPERATION AGREEMENT**

**A. Preamble**

1. This Cooperation Agreement (the “Agreement”) is made between Glenmark Pharmaceuticals, Inc. USA (“Glenmark”), the Attorneys General, as those terms are defined in the Settlement Agreement between them.
2. The purpose of this Agreement is to set forth the terms and process by which Glenmark will provide substantial cooperation to the Attorneys General in the Actions.
3. Glenmark on the one hand and the Attorneys General on the other hand agree that Glenmark’s substantial cooperation pursuant to this Agreement is material to the Settlement Agreement to be entered by them.

**B. Scope of Substantial Cooperation**

1. Glenmark agrees to use reasonable efforts to assist the Attorneys General to understand data produced by Glenmark, including consulting with technical personnel to address questions posed by the Attorneys’ General consultants, and to provide any additional information or data reasonably necessary to understand or clarify the data or otherwise render it usable by the Attorneys General’s experts and admissible.
2. The Attorneys General shall have the right to receive, subject to the protective order in the MDL, all documents, interrogatory responses, and responses to requests for admission produced by Glenmark to any other plaintiff in the MDL.

Glenmark likewise shall have the right to receive, subject to the protective order in the MDL and State Actions, all documents, interrogatory responses, and responses to requests for admission produced by the Attorneys General to any other defendant in the State Actions.

3. Glenmark agrees to use reasonable efforts to authenticate and lay the foundation to admit as business records, where applicable, collectively up to one hundred and fifty (150) documents and/or things produced by Glenmark in the Actions (or more if good cause is shown) to confirm the authenticity of the documents produced by Glenmark in the Actions, and to confirm, where applicable, that such documents and data produced by Glenmark qualify as business records, whether by declarations, depositions, hearings and/or trial testimony as may be necessary for the Actions to render such documents and data admissible at trial.
4. By no later than the day upon which the Attorneys General move for final approval of the Settlement, the Parties shall set forth any modifications to the scope of cooperation under this agreement in a separate letter agreement (signed by the counsel identified in this Settlement Agreement) among them to be provided to the Court if the Court so requires, and if so required, to be filed *in camera* with Court permission.

**C. No Waiver of Privileges, Evidentiary Protections, or Confidentiality Obligations**

5. Notwithstanding any other provision of this Agreement, Glenmark may assert where applicable the work product doctrine, the attorney-client privilege, and the common interest privilege (collectively, “Privileged Material”) and shall not

disclose any information provided by other defendants pursuant to a common interest agreement. The Attorneys General shall not request disclosure of Privileged Material, and a refusal to provide Privileged Material shall not be deemed a breach of this Agreement by Glenmark. The Attorneys General shall be free to use statements, testimony, materials or information provided under this Agreement in any motion, opposition or other pleading in the Actions or as evidence at trial in this case. The Attorneys General will not otherwise disclose any statements, testimony, materials or information provided under this Agreement to any other party in the Actions, including any other plaintiff, or to any third party unless required by applicable state law or court order. The Attorneys General and Glenmark are permitted to describe orally the scope of cooperation required under this Agreement with counsel for other defendants, but cannot otherwise disclose the information provided under this Agreement.

**Appendix D****Offset Amounts for Non-Settling States**

| <b>State</b>             | <b>Offset Amount</b> |
|--------------------------|----------------------|
| Alaska                   | \$19,888.99          |
| Arizona                  | \$227,937.03         |
| California               | \$1,157,512.80       |
| Colorado                 | \$138,613.31         |
| Connecticut              | \$232,586.62         |
| Delaware                 | \$32,337.24          |
| District of Columbia     | \$25,014.57          |
| Florida                  | \$325,294.44         |
| Georgia                  | \$215,156.05         |
| Idaho                    | \$32,881.17          |
| Illinois                 | \$304,018.09         |
| Indiana                  | \$175,723.11         |
| Iowa                     | \$88,802.27          |
| Kansas                   | \$59,382.89          |
| Kentucky                 | \$221,955.54         |
| Louisiana                | \$164,810.99         |
| Maine                    | \$38,079.72          |
| Maryland                 | \$178,542.48         |
| Massachusetts            | \$330,985.05         |
| Michigan                 | \$267,282.56         |
| Minnesota                | \$192,644.13         |
| Mississippi              | \$90,948.39          |
| Montana                  | \$32,282.83          |
| Nebraska                 | \$42,470.41          |
| Nevada                   | \$47,457.61          |
| New Hampshire            | \$29,429.06          |
| New Jersey               | \$241,142.75         |
| New Mexico               | \$65,653.08          |
| New York                 | \$853,633.06         |
| North Carolina           | \$323,106.78         |
| North Dakota             | \$14,550.63          |
| Northern Mariana Islands | \$1,684.29           |
| Ohio                     | \$446,157.32         |
| Oklahoma                 | \$96,904.33          |
| Oregon                   | \$118,554.91         |
| Pennsylvania             | \$396,027.71         |
| Puerto Rico              | \$120,143.89         |
| Rhode Island             | \$40,480.92          |



|                   |              |
|-------------------|--------------|
| South Carolina    | \$118,890.71 |
| South Dakota      | \$17,555.81  |
| Tennessee         | \$175,263.54 |
| US Virgin Islands | \$1,896.85   |
| Utah              | \$48,809.29  |
| Vermont           | \$31,289.33  |
| Virginia          | \$185,379.43 |
| Washington        | \$203,591.65 |
| West Virginia     | \$57,201.69  |
| Wisconsin         | \$187,197.11 |
| Wyoming           | \$12,082.98  |

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF  
CONNECTICUT

The State of Connecticut, *et al.*

Plaintiffs,

v.

3:16-cv-02056-MPS

Aurobindo Pharma USA, Inc., *et al.*

Defendants.

**SETTLEMENT AGREEMENT**

**SUPPLEMENTAL SETTLEMENT AGREEMENT BETWEEN GLENMARK  
PHARMACEUTICALS, INC., USA AND THE STATE OF ARIZONA**

This Supplemental Settlement Agreement is made and entered into by and among Glenmark Pharmaceuticals, Inc., USA (“Glenmark”), and the State of Arizona, by and through Attorney General Kristin K. Mayes (“Arizona”). Glenmark and Arizona shall collectively be referred to as the “Parties.”

WHEREAS, Arizona is prosecuting claims in *Connecticut et al v. Aurobindo Pharma USA, Inc., et al*, Case No. 3:16-cv-02056 (D. Conn.); *Connecticut et al v. Teva Pharmaceuticals USA, Inc. et al*, 3:19-cv-00710-MPS (D. Conn.); and *Connecticut et al v. Sandoz, Inc. et al*, 3:20-cv-00802-MPS (D. Conn.) upon remand from the multidistrict litigation in the Eastern District of Pennsylvania, *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Master Docket No. 16- MD-2724 (“MDL”), including *Connecticut v. Actavis Holdco U.S. Inc.*, No. 2:17-cv-03768 (E.D. Pa.) (collectively, the “Actions” or “State Actions”);

WHEREAS, Glenmark and Arizona agree fully to the terms of the SETTLEMENT AGREEMENT between Glenmark and the States (the “States Settlement Agreement”) except as amended below.

NOW, THEREFORE, in exchange for the mutual obligations described below and in the States Settlement Agreement, Glenmark and Arizona hereby enter into this Supplemental Settlement Agreement to modify the terms of the States Settlement Agreement between Glenmark and Arizona on the following terms and conditions:

**Glenmark and Arizona agree that the definition of “State Releasors” at Paragraph I.U. shall be deleted and replaced with the following:**

## I. DEFINITIONS

\* \* \* \*

U. “State Releasors” means the Attorneys General and State Entities listed on Appendix B (which include, among other State Entities, each State’s Medicaid agency). Notwithstanding the definition of “State Releasors” in the States Settlement Agreement, Glenmark and Arizona acknowledge and agree that portions of the Settlement Payment to be held in escrow in the Settlement Fund pending court approval of the States Settlement Agreement, as described in Section IX, may be distributed to Arizona state agencies other than the Office of the Arizona Attorney General and Arizona’s Medicaid agency. Glenmark and Arizona acknowledge and agree that any distribution to or acceptance of funds by any Arizona agency, other than the Office of the Attorney General and Arizona’s Medicaid agency, does not represent a binding acknowledgement by or for any of those agencies regarding the adequacy of the payments or a release of such agency’s claims, although acceptance of such payment may be grounds for an equitable set-off.

**Glenmark and Arizona further agree that Paragraph IV.A. of the States Settlement Agreement shall be deleted and replaced with the following:**

## IV. RELEASED AND RESOLVED CLAIMS

A. Arizona releases the Glenmark Releasees from all claims that Arizona brought or could have brought against the Glenmark Releasees (except on behalf of Local Entities and on behalf of Eligible Consumers) in the Actions brought by Arizona relating to the drugs specified in the Actions based on the Conduct as alleged, namely, antitrust, consumer protection, fraud or false claims act, “overarching conspiracy,” unjust enrichment and disgorgement claims. Except as required by A.R.S. § 41-193(A)(2), the Office of the Arizona Attorney General covenants not to sue the Glenmark Releasees for all claims that Arizona brought or could have brought against other defendants for any other drug for which Arizona asserts a claim in any of the States’ Actions based on the Conduct alleged in the States’ Actions. Released Claims include, but are not limited to, claims arising out of the Conduct under (1) federal or state antitrust laws, (2) unfair competition or consumer protection laws, (3) any civil or administrative monetary cause of action (including for civil damages and/or civil fines or penalties), (4) any remedies for any claims submitted or caused to be submitted to Arizona’s Medicaid program, including under the False Claims Act (codified at 31 U.S.C. §§ 3729-3733) or any Arizona counterpart to the federal False Claims Act, and (5) any other statute or common or equitable law. The claims released and the claims on which Office of the Arizona Attorney General covenant not to sue are collectively referred to as “Released and Resolved Claims.”

[SIGNATURES ON NEXT PAGE]

Dated: June 4<sup>th</sup>, 2026



Robert A. Bernheim, Unit Chief Counsel  
Antitrust & Privacy Unit  
Office of the Arizona Attorney General  
400 W. Congress St., Suite S-315  
Tucson, AZ 85701  
520-628-6507  
Robert.Bernheim@azag.gov

*Counsel for State of Arizona*

Dated: June \_\_\_, 2026

---

Dimitra Doufekias  
Morrison & Foerster LLP  
2100 L Street NW, Suite 900  
Washington, DC 20037  
(202) 887-1553  
ddoufekias@mofo.com

*Counsel for Glenmark  
Pharmaceuticals, Inc., USA*